initi coverag overweight pt bridgebio appli
eleg scienc mendelian/genet diseas attract strategi
rel favor risk/reward compani wed singl platform technolog
 rna refresh believ add anoth layer diversif
addit sub-bas oper structur also result effici clinic
develop year-end compani expect nda submit
clinic poc achiev product valuat base primarili
crown jewel fgfr oncology/achondroplasia ttr stabil pan-kra inhibitor
gene therapi program believ
provid plenti substrat futur similar structur
potenti receiv regn-lik platform valu via sever enorm
indic pursu
overal infigratinib/fgfr opportun robust believ
infigratinib nda file next year on-going trial support current
cholangio dataset launch anticip respect
model cholangio combin opportun
compani adjuv bladder cancer develop strategi differenti posit
candid ahead competitor anticip us launch sale
approach infigratinib tumor-agnost opportun also signific
model increment peak sale final includ achondroplasia
opportun infigratinib clinic poc data expect
initi describ multi-billion dollar attr opportun
repres holi grail kra inhibit though inhibitor
class gener signific investor excit recent address
kra cancer wherea pan-mut approach cover
two lead seri compound exhibit exquisit biolog drug candid select
expect ind follow month later success develop
could theoret gener global sale
gene therapi congenit adren hyperplasia appear
disrupt believ potenti elimin adren crise
need steroid competitor like proof concept data expect
success develop believ sale could approach
sale oncolog cholangio bladder
cardiomyopathi polyneuropathi
risk-adjust pan-kra sale lung
pancreat colorect risk-adjust
sale gene therapi
develop program exclud
model
page report also detail program includ potenti
dark hors inhibitor dual inhibitor
clinic develop risk infigratinib
bridgebio develop mendelian target oncolog gene therapi program
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tabl content
phase ii data attr-cm demonstr superior potenc
phase trial alreadi underway attr-cm like
page
page
page
topic inhibitor develop vm lm
page
loss-of-funct mutat drive gs hf-bcc
page
page
biotech compani headquart palo alto ca found
resourc develop commerci therapi area high unmet medic need
compani employ uniqu corpor structur place specif asset direct
control focus oper team date bridg gather diversifi asset-bas
portfolio span numer therapeut area modal four year compani
invest orphan genet diseas opportun categori
histor achiev biotech industri highest return unlik larg cap biotech
bridg avoid opportun base lower peak sale cutoff earli stage
develop back promin scientif founder believ bridg well-posit
consist deliv demonstr life-chang medic patient
bridg manag advisori team world-class consist highli success
respect pharma execut academ ceo dr neil kumar found member
serv vice-president busi develop prior princip
third ventur cso dr uma sinha previous cso global blood
therapeut held leadership posit variou
chairmen recogn leader respect field respect
individu industri brief snapshot background
oncolog dr frank mccormick director ucsf cancer center dean
ucsf school medicin former presid co-found first cso onyx
pharmaceut dr charl homci partner third ventur develop
market drug founder ceo director multipl biotech compani
research develop dr richard scheller former cso former
cso evp research earli develop genentech
three success track record develop product compani beyond
name member sharpest mind medicin chemistri clinic genet gene
therapi round bridg team
previous discuss bridg corpor structur allow leadership team focus
individu asset level asset oper subsidiari qed eido thera
adrena etc potenti increas decision-mak effici program
either cut invest littl bureaucraci compani belief
nimbl independ busi unit highli decentr allow effici drug
develop portfolio balanc high-risk high-reward asset sever
low-risk low-reward asset believ limit overal risk maxim reward
compani rapidli built diversifi portfolio product commerci program
fund earli stage new program per year clear ind per
year sinc bridg expect submit nda achiev clinic proof-
of-concept product demonstr preclin valid anoth
program believ bridgebio posit deliv signific valu patient
investor near long term
bridg effort focu mendelian genet diseas drug discoveri develop
histor lower risk faster provid higher return tradit drug discoveri
base deep understand genet context compani clearli identifi causal
target diseas aim treat approach replac directli modul
driver diseas bridg design effici clinic trial increas likelihood
success develop base condit compani estim three-fold higher
cumul probabl success faster develop time greater return
invest compar industri averag inde compani brought
page
advanc asset eido pellepharm patidegib phase ii complet
faster cheaper industri averag
backdrop effort gene therapi compani build intern expertis
conceptu develop aav-bas product includ recruit experienc
gene therapi develop avexi biomarin raymond bluebird van buren
novarti nv uncov format partnership lead academ lab co-
founder uncov aav vector optim product
establish enabl cro partnership like catalent/paragon bioservic
cover wieland becom difficult resourc secur
overal impress compani genetics-bas drug discoveri engin
initi data gener lead asset crown jewel program sever
value-cr catalyst near- mid-term four key valu driver compani
includ infigratinib eido
therapeut van buren stabil attr-cm
kra inhibitor kra mutation-posit cancer gene
therapi congenit adren hyperplasia highlight
infigratinib potent small molecul inhibitor receptor less affin
could afford less advers event clinic last year esmo bridg
present phase ii data evalu cholangiocarcinoma cca patient
found meaning improv standard care chemotherapi line later line
patient confirm orr diseas control rate cr pr sd
howev specif pure patient confirm orr note
respons rate patient nearli chemotherapi line addit
infigratinib therapi cohort provid month month os note
os nearli doubl provid standard care chemotherapi
patient infigratinib compar well fgfr inhibitor develop
cca includ van buren pemigatinib basilea/arqul
arql uncov derazantinib term safeti hyperphosphatemia common advers
event fgfr class due inhibit led treatment discontinu
patient adequ manag also believ import point infigratinib
treatment result lower rate diarrhea compar nail-rel
rel fgfr inhibitor could attribut infigratinib lower bind
affin toward base dataset expect nda file fusion-
posit cca year-end believ cca opportun
bridg also develop infigratinib first-lin cca standard care chemotherapi offer
respons rate limit durabl compani initi global phase proof
trial evalu infigratinib monotherapi vs gemcitabine/cisplatin chemotherapi current
recruit primari endpoint secondari endpoint os orr qualiti life
safeti pk compani expect infigratinib durat therapi improv
first-lin cca patient rel second-lin inde histor data tyrosin kinas
inhibitor tki demonstr signific improv move second-lin
first-lin set averag tki demonstr averag increas
move second first line given impress outcom second-lin patient
histor improv tki move second- first-lin believ
meaning treatment effect first-lin patient like infigratinib high chanc
provid advantag chemotherapi frontlin set top-line result
page
phase proof trial expect estim cca
opportun
beyond cca oncogen fgfr signal also observ urotheli carcinoma bladder
cancer fusion mutat found approxim muscle-invas diseas
upper tract diseas account case total us
alon infigratinib demonstr promis efficaci second-lin later
bladder cancer patient includ confirm orr dcr
competit landscap advanc metastat first-lin second-lin uc bladder
cancer set becom crowd continu develop immunotherapi
antibody-drug conjug fgfr inhibitor fgfr inhibitors/antibodi specif
jnj uncov balversa pemigatinib bayer uncov rogaratinib
rainier privat vofatamab develop tradit post-adjuv
first- second-lin set therefor bridg clever idea pursu earlier-lin
clinic strategi infigratinib adjuvant/post-surgeri set
current bridg prepar launch phase trial infigratinib adjuv high-risk
bladder cancer success would posit drug upstream
previous mention fgfr inhibitor competitor note standard care
adjuv set infigratinib clinic trial evalu efficaci compar observ
believ significantli increas program chanc success allow trial
smaller adapt design standard care demonstr superior
requir tradit program bayer infigratinib
adjuv trial expect studi period evalu disease-fre surviv
conclus common adjuv therapi trial note enrol high-risk
patient allow trial observ larg enough number progress event
control arm within time-frame though studi period like longer studi first
second line bridg believ enrol fast due larg pool patient
could allow trial enrol effici complet shorter overal timelin
jnj/incy/bayr trial bottom line bridg could first market adjuv
entrant compet later potenti shrink line therapi
model adjuv uc set opportun infigratinib
addit look forward initi data infigratinib tumor-agnost trial fgfr fusion-
posit cancer given preval fgfr fusion across numer tumor type view
opportun least three time greater loxo vitrakvi trk first
drug approv tumor agnost indic twice ret
demonstr promis clinic efficaci led acquisit uncov
januari also recal ignyta entrectinib trk inhibitor like vitrakvi bought
roch decemb estim tumor agnost opportun infigratinib
exceed
beyond oncolog gain-of-funct gof mutat gene drive
achondroplasia ach repres larg patient orphan diseas popul
given causal role aberr gof signal ach bridg believ infigratinib
potenti exhibit disease-modifi potenti directli bind pathogen sourc
block multipl signal cascad lead downregul chondrocyt prolifer
chondrocyt hypertrophi import bone growth occur ach patient
compani believ infigratinib like viabl fgfr inhibitor use
patient due best-in-class safeti profil observ oncolog patient
page
manifest diseas preclin data thu far indic best-in-class potenti
term long-bon respons infigratinib-tr mice exhibit increas
femur length increas tibia length demonstr col immunostain marker
chondrocyt differenti increas bone growth activ growth plate infigratinib-
treat mice result suggest infigratinib therapi could lead increas height
proportion patient addit infigratinib treatment afford increas foramen
magnum area skull open spinal cord pass increas
length increas disc width note infigratinib compound
develop ach shown posit effect foramen magnum area
prevent sever foramen magnum narrow well compress spinal column
could lead signific decreas seriou correct surgeri patient overal believ
preclin data provid impress proof-of-concept infigratinib potenti activ
compani believ infigratinib like efficaci agent
transcon theracon uncov infigratinib modul
pathway affect chondrocyt prolifer hypertrophi directli bind
driver diseas rather modifi bystand signal cascad inde cnp
dampen pathway therefor alter chondrocyt prolifer
small molecul infigratinib effici reach growth plate dysfunct
chondrocyt locat less clear therapi includ theracon
could experi diffus issu similar antibodi whose
ach program discontinu lack efficaci base differenti featur
believ bridg infigratinib could attract candid ach among
bridg plan launch proof-of-concept phase i/ii studi ach patient year bridg
current conduct final preclin toxic studi infigratinib highly-
engag fda clinic studi design compani believ enrol patient
year old rang similar vosoritid trial bridg anticip rapid proof-of-
concept biomark col previous discuss correl long
bone growth evalu earli cours treatment along long-term
measur includ growth veloc notabl bridg anticip larg therapeut
index consid dose administ ach patient lower
dose administ oncolog patient significantli lower lowest dose
hyperphosphatemia observ initi data trial expect base
highly-differenti robust mechan action conveni oral dose believ
infigratinib captur market share amount global sale
oral small molecul tablet potenti halt progress transthyretin
ttr amyloidosi bind stabil ttr tetram blood therebi prevent
toxic accumul misfold ttr monom cardiac tissu caus heart failur
mimick naturally-occur variant ttr gene rescu
mutat observ human protect attr-cm therefor treatment
lead reduct ttr monomer patholog driver attr
approach eido aim improv clinic outcom patient suffer attr-
cm pn like competitor vyndaqel tafamidi uncov
page
recent approv street project multi-billion dollar drug eido aim
treat root caus attr-cm maintain serum concentr ttr tetram
essenti blood carrier vitamin hormon thyroxin eido believ
small molecul oral stabil may best-in-class come improv patient
outcom patient wild type wt mutant form diseas inde
tafamidi bind thyroxin ligand bind pocket ttr tetram
three distinct differ two molecul bind two site within
pocket tafamidi bind one bind enthalpy-driven word
energet favor non-coval attract forc hydrogen bond dictat
bind hand tafamidi form hydrogen bond therefor
confer amount stabil two molecul capabl bind
differ proport ttr tetram tafamidi bind albumin high affin observ
kinet tafamidi bind seen follow treatment albumin act like spong absorb
tafamidi result plateau efficaci higher dose level affect
albumin therefor bind higher amount tetram
respect data present date encourag dataset
phase ii trial discuss detail report shown high rate
ttr stabil treat patient wild-typ wt mutant symptomat attr
cardiomyopathi believ increas stabil result increas serum ttr
concentr clinic meaning
recent public hanson et al show increas ttr level blood lead
decreas patient mortal risk addit appear clinic differenti tafamidi
complet stabil ttr versu tafamidi stabil
lead rel superior serum ttr concentr previous mention versu
increas tafamidi achiev per studi mention
also lead improv mortal efficaci relat long-term outcom rate
patient mortal frequenc hospit visit cardiovascular-rel morbid
evalu phase ii ole trial data due updat also
expect receiv echo paramet biomark ttr tnl bnp could also
inform data updat meaning begin think final phase
note alreadi seen improv patient outcom result vyndaqel therapi
month vyndaqel associ lower mortal placebo vs
curv diverg approxim month treatment also
associ lower rate declin distanc walk test lower
rate declin kansa citi cardiomyopathi questionnaireoveral summari kccq-o
score consid data provid signific de-risk program
provid clinic proof-of-concept attr-cm patient increas probabl phase
success previous state tafamidi appear inferior tetram stabil
level compar previous discuss correl ttr stabil
patient outcom hold true expect morbid mortal rate improv
ioni van buren alnylam tenthoff also investig clinic
candid attr-cm howev drug treat less preval mutat popul
less preval wt attr-cm wherea treat ttr patient regardless
mutat statu also like price higher therefor see
compani major competit threat attr-cm
superior potenc
page
phase trial
base posit phase ii experi follow extens interact fda
registr phase attribute-cm trial recent initi trial
expect enrol patient establish diagnosi attr-cm either wt
mutant ttr genotyp compani current enrol conduct two part
part evalu minut walk distanc test month part evalu
mortality/hospit month later month design attribute-cm provid
opportun near-term regulatori approv base allow compani
opportun trial expand label includ mortal morbid base
month readout label expans base mortal morbid signific commerci
implic look compet vyndaqel
design care select base approv vyndaqel use
registr endpoint trial estim take approxim year enrol
believ achiev consid attr cardiomyopathi patient identifi
higher rate due vyndaqel launch eido complet enrol phase
ii studi one month manag believ suffici approv
receiv clear guidanc fda ema approv like success
outcom month long observ detriment mortal
believ like case given safeti data collect date
key goal also increas patient diagnost order identifi patient like respond
small molecul ttr stabil variou factor contribut improv patient
identif includ use pyrophosph imag compani
believ inevit increas result vyndaqel approv moreov eido began
commerci prepar upon initi phase studi compani begun patient
research kol develop plan engag patient advocaci group gain
understand patient issu data alreadi collect understand diseas preval
use diagnosi rate look patient popul heart failur preserv
eject fraction seen diseas current diagnos commerci
plan place includ full sale market market access capabl compani
estim current diagnos patient attr-cm us
increas use pyp scan diagnosi number may actual high
bottom line expect superior degre ttr stabil translat improv
clinic outcom phase eventu approv estim global sale
could well conserv
eido also conduct phase trial attr polyneuropathi diseas
driven amyloid deposit mechan attr cardiomyopathi except deposit
primarili impact nerv trial expect begin second half year take
approxim month enrol report top-line data given similar
mechan reduc format amyloid deposit via ttr stabil believ trial
high likelihood success could result snda file shortli thereaft
potenti approv success develop believ could gener
sale indic understand gene silenc competitor tegsedi onpattro
current launch believ stabil could differenti via mechan
price well
worth noth vyndaqel shown achiev short-term delay peripher neurolog
impair stage attr-pn howev studi show prevent
progress nerv damag major adult patient reason
approv ema fda also recal data gener ago
dose significantli lower current formul market cardiomyopathi
page
therefor believ better clinic outcom possibl higher dose potent
indic current eido pipelin compani note good
start point may treat patient pyp scan-posit ttr dont heart
kra well-known oncogen driver cancer success target protein
consid holi grail oncolog remark cancer harbor kra mutat
includ lung colorect pancreat cancer altogeth
repres greater patient per year us eu recent kra
undrugg oncogen due lack hydrophob bind pocket surfac
addit barrier caus highly-st kra mutant-gtp complex prevent
easily-predict high-affin small molecul bind disrupt signal breakthrough
made target switch region discov
exploit next-gener kra inhibitor van
buren raymond jnj/wellspr
function lock oncogen gdp-bound posit initi phase dose-
escal data program demonstr respons rate
lung cancer patient drum signific investor excit kra inhibitor
class said inhibitor address kra mutation-posit popul
bridg develop pan-mut kra inhibitor potenti
treat mutant form kra program led dr frank mccormick refer
king kra pioneer novel approach target oncogen kra
mutation-agnost manner compani pursu two approach parallel includ
binder prevent kras/cel membran associ similar mechan
oncolog van buren tipifarnib binder trigger degrad activ
gtp-bound kra target modal potenti bind kra mutant
previous discuss could allow therapi treat patient harbor
kra mutat pan-mut kra inhibit approach attract inhibitor
would retain activ mani patient expect develop site-specif mutat mutation-
specif inhibitor inde compani believ pan-mut kra
approach could less prone treatment-resist mutat would therefor
durabl compound target main catalyt domain kra like inhibitor
futur site-specif inhibitor class
program built core astonishingli effici capit resourc
cooper research develop agreement crada nci lawrenc
livermor nation laboratori nci compani centerpiec
govern invest focu ra call ra initi head thera
scientif founder dr frank mccormick within ra initi work conduct
thera prioriti project compani access cross-disciplin team
scientist lawrenc livermor nation laboratori compani access
comput hour perform comput chemistri power
supercomput world theras/bridgebio leverag resourc simul ra activ
identifi refin novel drug strategi effort nation lab led progress
identifi key featur kra protein structur reveal novel drug bind
pocket preview notabl crada allow bridgebio exclus licens
compound develop collabor
page
bridg advanc pan-kra candid binder reactiv cystein
residu locat hypervari region hvr tail ra protein farnesyl transferas
geranylgeranyl transferas add lipid order allow ra protein anchor
cell membran membran tether requir convers inact kras-gdp
activ kras-gtp blockad event transferas could inhibit cancer growth
thu make attract target molecular model perform collabor
nation lab bridg discov initi binder also modifi area ra
evid tail fold back onto main bodi kra protein
interact previous undescrib g-domain/switch ii region near shokat pocket
pocket amgn mrtx jnj/wellspr kra inhibitor bind
observ suggest bridg robust interact exist region
hvr kra structur theoret creat novel druggabl
pocket bridg refer druggabl structur pocket compani
hypothes pocket may abl target stabil
binder success target forc complex remain close posit
lead binder demonstr recruit addit stabil interact among
pocket secur inhibitor bind addit bridg learn lead
compound bind predomin oncogen kra splice variant creat
potenti select kra ra protein includ hra nra
compound demonstr pan-mut inhibit potenti binder treatment
specif reduc level compani believ kra
deplet result increas cytosol vesicl recycl proteasome-medi degrad
sinc find initi lead bridg increas cellular potenc past
two year result sub-micromolar compani also shown
drug candid highly-select mutant kra wildtyp kra
import provid high therapeut index clinic compani current work
improv inhibitor potenc across kra mutant variabl current present
addit binder program discuss bridg current work
seri compound bind region uniqu residu
isoform conserv form mutant kra highlight resid
pocket form result hvr fold onto g-domain/switch ii region
kra molecular model experi suggest exist druggabl pocket
requir concomit bind therefor present distinct drug
discoveri opportun area locat g-domain next shokat pocket
expos kra activ gtp-bound state import mutant kra larg
exist activ state ratio inact gdp-bound protein recal
inhibitor bind inact gdp-bound state initi lead binder shown specif
reduct phospho-akt suggest bind critic effector kra
significantli impair result ubiquitination-medi degrad
previous implic drive ras-medi tumorigenesi mainten compani
believ abil inhibit effector function ra potenti signific bridg
believ first put inhibitor effector bind kra aggress
pursu mechan
drug candid select bridg pan-mut kra inhibitor program expect
ind follow month later success develop peak sale could
potenti surpass make one largest drug pharmaceut industri
page
gene therapi congenit adren hyperplasia rare inherit
autosom recess disord debilit life-threaten case
caus inactiv mutat gene account product
hydroxylas enzym defici defici send cortisol/acth homeostasi
disarray uninhibit acth primarili direct androgen product
render patient unabl produc cortisol aldosteron produc excess
testosteron lead fatal adren crise
adeno-associ gene therapi codon-optim
transgen constitut activ promot design allow patient
achiev homeostat control adren hormon treat root caus diseas
defici express transgen replac defect gene
transduc adren cortex cell produc replac essenti enzym
restor activ natur hormon steroid cycl increas aldosteron
cortisol product reduc testosteron therefor risk adren crisi
clear genotype-phenotyp relationship enzym activ patient
clinic manifest inde patient lack product diseas symptom
sever patient sever symptom salt-wast diseas express normal
level make roughli patient defici patient
express higher level chanc experienc adren crisi dramat reduc
fact natur histori studi conclud threshold level normal express
g/dl protein may prevent adren crisi note analog factor
replac requir gene therapi approach revers phenotyp hemophilia patient
interestingli wild type product patient asymptomat
demonstr abil transduc adren cortex cell produc non-
human primat nhp suggest potenti restor natur hormon
steroid cycl disrupt patient rna level increas dramat
nhp week three dose use
unsurprisingli highest rna express seen highest dose week
specif rna level increas dramat nhp
week three dose use despit small declin vgc
week adren due vector unpack occur prior gene
express overal data suggest signific transduct adren
suffici vector genom count mrna express three month follow singl dose
data key assess durabl move forward
see soon havent seen data compani note durabl still
observ time point
compani pursu preclin develop explor
relationship phenotyp correct rna level mous model order
establish minim effect dose help bolster preclin proof-of-concept
suggest increas rna level like observ nhp studi may correl
phenotyp correct assess effect structur function
adren medulla cortex overal frailti stress level assess
previous addit lot manufactur compani
use initi glp toxic studi specif studi look whether
steward pathway may mediat hypertens complic
everyth consid bridg track file ind initi clinic proof
concept data expect trial like dose-rang phase studi adult
page
patient year age compani would like eventu expand pediatr dose
arm well
believ gene therapi approach like make meaning differ
patient competitor program neurocrin amsellem
privat tildacerfont antagonist millendo
therapeut uncov inhibitor name agent work
attenu product adren androgen address root caus
like still requir life-long steroid supplement rais major safeti concern patient
easili under- over-dos may suffici resolv diseas burden
patient key competit advantag bridg dramat reduc
even elimin need steroid supplement correct diseas root
caus patient world-wide believ sale could approach
addit program discuss bridgebio develop addit asset
span therapeut area modal includ small molecul gene therapi
detail statu program result market opportun discuss
toward end report includ
synthet replac cpmp type molybdenum cofactor defici
intravenously-deliv recombin collagen type vii treat system
manifest rdeb
transderm inhibitor venou lymphat malform
alloster modul pantothen kinas pantothen kinas
associ neurodegener pkan organ acidemia oa
small molecul glycol oxidas go inhibitor primari hyperoxaluria
topic small molecul supplant lekti function skin
succin prodrug therapi leber hereditari optic neuropathi lhon
gene therapi canavan diseas
topic formul small molecul hedgehog inhibitor gorlin syndrom
inhibitor multipl tumor set
inhibitor key anti-ferroptot factor multipl tumor
page
view import near-term mileston compani
data phase ii ole studi attr-cm
updat phase ii dataset infigratinib mutant/fus bladder
cancer year-end
nda file infigratinib
drug candid select kra inhibitor
ind file gene therapi
page
product/programeventindicationexp stabilizereido ownership phase enrol ii ole inhibitorqedproof trial vs gem/ci soc fusion cca nda fusion phase ii mutant/fus bladder uc phase first patient fusion adjuv bladder ii basket trial enrol osu/orien consortiumtumor-agnost fgfr fusion-posit ongoingphas i/ii first patient proof-of-concept gene therapyadrenasind filingcongenit adren proof-of-concept datacongenit adren inhibitortherasdrug candid selectionkra cpmp origincomplet ndamocd type collagen type viiphoenix tissu repairtoplin phase i/ii resultsrecess dystroph epidermolysi inhibitorventheraind submissionven lymphat activatorcoa submissionpkan organ inhibitororfandrug candid selectionprimari hyperoxaluria dual inhibitormostind submissionnetherton pro-drugfortifydrug candid selectionleb hereditari optic gene therapyaspaind submissioncanavan inhibitorpellepharm outlicens nda submissiongorlin inhibitornavireind submissionrtk-driven inhibitorferrodrug candid selectionrcc pancreat nhl sarcoma dcf-base
use dcf model valuat methodolog run incorpor
long patent live bridg develop candid current model global sale
infigratinib three oncolog set cca adjuv bladder cancer
tumor agonist set ach infigratinib ip protect
tier low double-digit mid-teen royalti owe
second-lin later assum launch infigratinib
us ex-u second-lin set current model
month treatment durat base current clinic dataset treatment
elig patient result global sale
first-lin set estim us launch ex-u launch
one year later result global sale
total believ infigratinib opportun could reach
base treatment elig patient
 adjuv urotheli cancer estim infigratinib first launch
muscle-invas indic us upper tract diseas one
year later also expect ex-u market introduct
indic one year respect us launch model penetr
elig patient result global sale
tumor agnost set estim infigratinib launch
us one year later ex-u result sale base
treatment elig patient
togeth opportun infigratinib oncolog reach
 ach model launch us ex-u one year later
base highly-differenti robust mechan action
conveni oral dose believ infigratinib captur market share
amount global sale
eido attr cardiomyopathi consid previous mention pivot
trial timelin assum approv launch us
sale gener ex-u model sale time total
global consider composit patent last earli
possibl extens
sale non-smal cell lung metastat pancreat
metastat colorect cancer set estim launch kra
mutation-posit cancer us ex-u one year later
believ global sale reach believ peak
sale could eventu reach make one largest drug
pharmaceut industri given earli stage develop current risk-adjust
estim model appli probabl success given histor
benchmark success oncolog orphan drug develop stage ip protect
expect low singl digit royalti owe
page
gene therapi assum launch
us believ sale possibl ex-u believ
launch one year later could occur sale possibl
period therefor success develop believ could
gener global sale approach given earli stage develop
current risk-adjust estim model appli probabl
success given histor benchmark success non-oncolog orphan drug
develop stage
assum eventu gross margin bridgebio high industri standard
oper spend lead oper profit compani time-frame
note bridgebio own vast major subsidiari non-bridg ownership
need off-set via non-control interest line bottom largest
contribut line eido bridg ownership
discount futur cash flow back discount rate account remain clinic risk
associ infigratinib heavili risk-adjust revenu
result fully-dilut equiti surpass per fully-dilut share basi
price target note de-risk clinic program would like result
either subsequ lower discount rate increas risk-adjust revenu
could result significantli higher share price also dont includ
program develop model discuss later report bridgebio
numer program target multi-billion dollar product opportun note one
could signific impact overal compani valuat final bridg
corpor structur similar ultim believ compani
receiv regn-lik platform valuat one compani sever blockbust
program hit market
page
fiscal year end revenu cca cca launchuc amibc autbc tumor agnost indicationexpect ip oncolog launcheu launchexpect ip achondroplasia launcheu launchstanford composit patent expir attr cardiomyopathi kra lung pancreat colorectalexpect ip oncolog salesrisk launchexpect ip salesrisk collabor bridgebio good develop revenu gener revenu expens revenu incom incom loss interest incom expens non-oper loss revenu estim net incom loss interest eido incom loss earn per outstand
page
assumpt output mm tyler van buren share outstand share biotech analyst increas work capit term discount valuationfisc year end bridgebio good develop revenu gener revenu expens revenu stock incom tax oper profit work capit valuepiperjaffray
fibroblast growth factor receptor fgfr tyrosin kinas signal pathway known
essenti role numer biolog set includ embryon develop cell prolifer
differenti angiogenesi four highly-conserv fgfr receptor
critic signal transduct downstream activ fgfr signal known
increas mapk stat plc pathway recent aberr fgfr signal
caus gene fusion activ mutat found play role
oncogenesi across rang tumor type exhibit
given histor success target tyrosin kinas signal receptor includ egfr
nsclc kit gastrointestin stromal cancer breast cancer target
fgfr pathway becom great clinic interest due develop specif inhibitor
compound target kinas activ domain fgfr prevent oncogen signal
tumor posit fgfr alter current patient cancer harbor fgfr
mutat treatment option larg poor outcom exampl second-lin
set post first-lin combin chemotherapi orr genetically-unselect patient
cholangiocarcinoma cca rare bile duct cancer approxim short
progression-fre surviv overal surviv roughli cca patient harbor
fusion amount incid case us eu per year
patient could benefit target therapi addit bladder cancer
higher incid case fgfr inhibitor also like develop tumor-
agnost manner similar loxo oncology/bay uncov vitrakvi trk-fusion
posit cancer fgfr fusion found tumor annual case
therefor success develop fgfr inhibitor could improv outcom signific
number patient
page
infigratinib potent small molecul inhibitor receptor less affin
could afford less advers event clinic qed acquir infigratinib
novarti nv uncov program depriorit follow phase i/ii basket trial
infigratinib target type fgfr genet alter block tumor driver sourc
compani lead program cca bladder cancer
posit clinic dataset multipl growth opportun exist two indic
discuss individu follow text
addit infigratinib six fgfr inhibitor develop demonstr
vari rang vitro activ across four fgfr exhibit appropri clinic
comparison made text
qed assembl veteran team experi develop launch
molecul includ led launch imbruvica ibrutinib indic
pharmacycl acquir former vice-president clinic
develop puma uncov led neratinib earli adjuv
breast clinic program whose experi advantag qed navig
adjuv set clinic program bladder cancer infigratinib describ later bottom
line believ commerci clinic depth qed manag team
prove invalu infigratinib futur success
first-lin cca patient treat primarili gemcitabine/cisplatin chemotherapi
see respons rate near rel short progression-fre surviv second-lin
patient fare much wors limit treatment option set second-lin standard
care chemotherapi typic provid overal respons rate orr month
month overal surviv os therefor qed believ fgfr inhibit like becom
standard care cca patient harbor fusion improv
outcom first- second-lin
qed enrol second-lin later phase ii trial cca compris primarili
sever patient later patient exhibit stage iv
diseas phase i/ii tumor-agnost trial previous run novarti nv uncov
maximally-toler dose infigratinib found qd patient need
treatment interrupt day let hyperphosphatemia known advers event fgfr
inhibitor recov though effect larg subclin natur qed adjust
page
dose regimen phase ii trial cycl week qd dose follow
week allow phosphat level recoveri
last year esmo qed present phase ii data evalu cca
patient found meaning improv standard care chemotherapi exhibit
line later line patient confirm orr diseas control
rate cr pr sd orr intent-to-treat popul
specif pure patient confirm orr note
respons rate patient nearli chemotherapi line respons
rate infigratinib appear in-lin better competitor pemigatinib derazantinib
especi sever patient popul taken account
page
cholangiocarcinomadrugstandard care chemo schedulep prescrib qd day qd day qodtrialmeta-analysisphas iiphas iiphas i/iicompanyn/aq therapeuticsincytearqule/basilealatest sourcelamarca et al press releasedata line prior therapi dataoveral respons respons respons diseas control rate cr pr respons rate patient durat respons progress free surviv estimate overal surviv reachedcontinu waterfal plot best respons patient achiev phase ii trial suggest
infigratinib therapi provid diseas control vast major patient exhibit
note patient potenti complet cycl treatment includ
waterfal plot analysi tumor reduct base investig read
independ central read result updat later year like esmo qed
enrol addit patient cohort sinc last data cut whose result could
includ esmo data updat well
infigratinib therapi cohort provid month month os
os nearli doubl provid standard care chemotherapi patient
swimmer plot show infigratinib-tr patient time data cutoff maintain
respons month remain therapi exhibit
page
infigratinib compar well fgfr inhibitor develop cca
includ pemigatinib basilea/arqul derazantinib
cover van buren pemigatinib last updat esmo
demonstr evalu patient achiev respons
respons rate pemigatinib larg similar
infigratinib exhibit main differ two clinic program
dose schedul week week pemigatinib vs week week
infigratinib qed believ waterfal plot pemigatinib infigratinib overlay pretti
well note baselin criteria enrol patient two cohort
differ one pemigatinib cohort enrol adjuv first-lin
second-lin patient infigratinib cohort second-lin greater
secondli pemigatinib cohort stage iv diseas compar infigratinib
therefor qed believ infigratinib offer least compar efficaci rel
pemigatinib difficult treat patient popul current pemigatinib
demonstr higher mpf month os month compar
infigratinib number could chang patient ad efficacy-
evalu popul note mpf os outcom
pemigatinib could inflat rel infigratinib patient popul rel
basilea/arqul bpmuf/arql uncov derazantinib dose
qod demonstr orr dcr per januari
page
press releas data cut look similar data
updat date mpf month trail infigratinib
pemigatinib continu gener concern kol qt
prolong derazantinib-tr patient due compound affin
though observ clinic date given current dataset qed
believ derazantinib could one year behind second-lin
indic therefor potenti third fgfr inhibitor market
term safeti common reason dose reduct hyperphosphatemia
on-target advers event due inhibit importantli hyperphosphatemia
led treatment discontinu patient adequ manag phosphat
binder dose adjust patient requir dose reduct stay treatment
qed note durabl diseas control observ patient
dose suggest dose regimen effect balanc efficaci safeti lower
rate diarrhea compar nail-rel observ date
rel fgfr inhibitor class could attribut lower bind affin
toward advers event observ patient treat infigratinib
lower exhibit
given clinic profil date qed submit nda infigratinib second-lin
compani believ nda submiss good shape
current prepar commerci launch note qed commerci effort
led season veteran pharmacycl qed commerci team concentr
one asset one indic compani believ focu offer signific competit
advantag other commerci fgfr inhibitor space current qed estim
prescrib reach site suggest commerci
launch could success execut small dedic sale forc
first-lin cca standard care chemotherapi offer respons rate limit durabl
qed also develop infigratinib first-lin cca compani initi
global phase proof trial evalu infigratinib monotherapi vs gemcitabine/cisplatin
page
indicationdruginfigratinibpemigatinibderazantinibtrialphas iiphas iiphas i/iicompanyq therapeuticsincytearqule/basilealatest sourceesmo press releasedata lead tx discontinu cholangiocarcinoma
chemotherapi current recruit primari endpoint secondari endpoint
os orr qualiti life safeti pk trial design allow crossov infigratinib
progress gemcitabine/cisplatin chemotherapi top-line result expect
though qed find infigratinib therapi second-lin patient alreadi offer patient
rel better outcom first-lin patient treat standard care chemotherapi
compani expect infigratinib durat therapi improv first-lin cca
patient rel second-lin inde histor data tyrosin kinas inhibitor
tki demonstr improv move second-lin first-lin set
averag tki demonstr month averag increas move
second first line given impress outcom second-lin patient histor
improv tki move second- first-lin believ meaning treatment
effect first-lin patient like infigratinib high chanc provid
advantag chemotherapi frontlin set
also conduct first-lin trial cca trial initi decemb similar
qed evalu pemigatinib monotherapi vs gemcitabine/cisplatin chemotherapi given
similar natur clinic strategi qed believ largest differenti two
program speed enrol therefor overal timelin trial far
tell two program appear neck neck
us approxim new cca patient per year grow rate
year year approxim half patient exhibit advanc metastat diseas
refractori first-lin therapi estim patient harbor
mutat candid infigratinib therapi second-lin later
assum launch infigratinib us price per month slight increas
rel jnj balversa g/n price increas per year also assum ex-
us launch well addit cca case per year
page
second-lin set current model month treatment durat peak penetr
elig patient result global sale first-lin
set estim us launch ex-u launch one year later
frontlin current model month treatment durat given histor increas
observ tki move second- first-lin estim peak penetr
elig patient result global sale total believ
infigratinib opportun could reach
beyond cca oncogen fgfr signal also observ urotheli carcinoma bladder
cancer fusion mutat found approxim muscle-invas diseas
upper tract diseas account case total us
alon mutat believ result higher rate cancer cell prolifer
urotheli line promot higher rate mutat burden support transit higher-
grade invas diseas studi shown bladder cancer patient
harbor mutat typic exhibit immunologically-cold tumor respond well
current immunotherapi includ antibodi thu fgfr inhibit repres
promis agent patient whose diseas depend signal
page
fiscal year end cholangiocarcinomacholangiocarcinoma cca patient advanc metastat unresect a/m/u cca cca patient refractori cca patient a/m/u a/m/u cca patient a/m/u patient refractori a/m/u cca patient treat infigratinib a/m/u patient refractori launchrefractori posit a/m/u cca patient treat refractori a/m/u cca patient durat treatment price per price per patient us sale stateseu launchinfigratinib ex-u sale cholangiocarcinomacholangiocarcinoma cca patient advanc metastat unresect a/m/u cca a/m/u cca patient a/m/u cca posit a/m/u cca patient treat a/m/u cca patient durat treatment price per price per patient us sale stateseu launchinfigratinib ex-u sale worldwidetot infigratinib ww
date infigratinib demonstr promis efficaci second-lin later
bladder cancer patient report pal et al infigratinib therapi demonstr
confirm orr dcr patient enrol phase studi exhibit
includ efficaci upper tract uc diseas saw orr diseas
control rate data particularli impress given upper tract diseas typic
associ poor prognosi fewer treatment option rel urotheli cancer gener
recent qed provid updat upper tract diseas patient
show infigratinib treatment provid patient month median os
patient respond therapi averag tumor reduct observ exhibit
page
urotheli qd day qd day qd qw docetaxeltrialphas iphas iiphas iiphas iphas iicompanyq therapeuticsincytejnjbayerraini therapeuticslatest sourcep et al line prior therapi dataoveral respons respons respons diseas control rate cr pr durat respons progress free surviv overal surviv exhibit
patient baselin least one post-baselin assess includ figur
data current base investig read central read
complet soon note one complet respons observ compani
note rare posit outcom late-lin solid tumor clinic trial
median durat respons phase trial month exhibit
page
mpf os heavili pre-treat popul month
respect believ result provid proof-of-concept infigratinib activ
alter bladder cancer howev current infigratinib result trail incyt pemigatinib jnj
uncov balversa term durat respons mpf os
term safeti infigratinib profil bladder cancer patient larg similar observ
cca fgfr inhibitor develop indic howev note
infigratinib caus nail eye toxic like erdafitinib presum due lower
page
though infigratinib activ treatment metastatic/unresect bladder cancer
competit landscap advanc metastat first-lin second-lin set becom
crowd continu develop immunotherapi antibody-drug conjug
fgfr inhibitor fgfr inhibitors/antibodi specif jnj balversa
pemigatinib bayer bayri uncov rogaratinib privat
vofatamab develop tradit post-adjuv first- second-lin set
led qed gener differenti early-lin clinic strategi infigratinib
adjuvant/post-surgeri set
current qed prepar launch phase trial infigratinib adjuv high-risk
bladder cancer success would posit drug upstream
page
urotheli carcinomadruginfigratinibpemigatiniberdafitinibrogaratinibvofatamabtrialphas iphas i/iiphas iiphas iphas iicompanyq therapeuticsincytejnjbayerraini therapeuticslatest sourcep et al serou ocular lead tx discontinu exhibit
anoth advantag go earlier treatment paradigm treatment durat
significantli longer adjuv therapi typic greater one year compani view
opportun adjuv therapi post-surgeri set muscle-invas diseas upper
tract diseas highly-attract due absenc standard care interestingli
mutat found muscle-invas diseas found
upper tract diseas suggest fgfr inhibit could prove meaning way stall
importantli well standard care adjuv set infigratinib clinic
trial evalu efficaci compar observ believ significantli increas
program chanc success allow trial smaller adapt design
standard care demonstr superior requir tradit
program bayer infigratinib adjuv trial expect
year studi period evalu disease-fre surviv conclus common
adjuv therapi trial note enrol high-risk patient allow trial
observ larg enough number progress event control arm within time-frame
though studi period like longer studi first second line qed believ
enrol fast due larg pool patient could allow trial enrol
effici complet shorter overal timelin jnj/incy/bayr trial
bottom line qed could first market adjuv entrant
compet later potenti shrink line therapi
qed close monitor infigratinib safeti profil trial success adjuv
therapi requir patient remain treatment long possibl hyperphosphatemia
observ frequent past compani believ pose
signific concern long-term toler qed discov infigratinib pk differ
slightli amongst patient believ patient start dose order give
best chanc efficaci dial-down need clinic trial experi date patient
longest treatment durat drop lower dose none discontinu
therapi due hyperphosphatemia suggest potenti favor long-term
page
us approxim patient muscle-invas bladder cancer
harbor mutat addit patient
upper tract diseas harbor mutat current
standard care post-surgeri adjuv therapi type bladder cancer
estim infigratinib first launch muscle-invas indic us
upper tract diseas one year later also expect ex-u market introduct
indic one year respect us launch current assum treatment durat
one year may prove conserv given typic long durat therapi
observ adjuv set price per month slight increas rel
jnj balversa g/n price increas per year model penetr
elig patient result global sale
beyond name indic cca bladder cancer fgfr mutat found
oncogen driver larg number tumor type fgfr fusion occur cancer
amount patient per year us eu cancer exhibit fgfr fusion
repres fgfr-alter cancer includ cca bladder cancer
previous discuss also glioma pancreat exocrin carcinoma endometri
adenocarcinoma renal cell carcinoma breast cancer exhibit
page
fiscal year end statesadjuv muscl bladder cancerbladd cancer bc patient urotheli carcinoma bladder cancer bc patient muscl invas mi uc bc mibc patient uc bc patient mi uc mibc patient treat uc mibc patient durat treatment price per per patient us adjuv uc mibc sale stateseu launchinfigratinib ex-u adjuv uc mibc sale statesadjuv upper tract bladder cancerbladd cancer bc patient urotheli carcinoma bc patient upper tract ut bc utbc patient uc bc patient ut uc utbc patient treat utbc patient durat treatment price per per patient us adjuv uc utbc sale stateseu launchinfigratinib ex-u adjuv uc utbc sale worldwidetot infigratinib ww adjuv muscl invas upper tract uc bc sale exhibit
loxo/bay success target trk pathway vitrakvi give us confid
potenti tumor-agnost activ infigratinib genetically-defin patient respons
vitrakvi shown independ age tumor type ntrk mutat fusion
partner qed believ target inhibit fgfr pathway may provid clinic benefit
genetically-defin patient whose tumor driven fgfr note tumor-agnost
opportun infigratinib could trk/vitrakvi
note earlier novarti previous conduct phase i/ii trial infigratinib trial
basket studi recruit patient type tumor infigratinib provid respons
differ tumor type fgfr fusion includ glioma gallbladd cancer carcinoma
unknown primari cca bladder cancer
investigator-sponsor phase ii basket studi evalu infigratinib numer fgfr-fusion
posit cancer current open ohio state univers orien consortium
notabl infigratinib fgfr inhibitor develop tumor agnost set
addit qed intend pivot studi company-sponsor registr trial
proof-of-concept achiev
conjunct clinic program qed also conduct translat program head
former head translat biolog ignyta acquir roch aim
identifi appropri fgfr-fusion patient infigratinib therapi includ two part
includ evalu dna rna-bas biopsi sequenc longitudin
biomarker-bas follow-up preclin research program probe fgfr fusion across
tumor type relev preclin model qed believ sequenc biomark data
could inform scope registr program
previous discuss fgfr fusion repres larg opportun patient
us eu estim infigratinib launch tumor agnost set us
treat elig patient result sale ex-u model
infigratinib launch tumor agnost set similar penetr rate time
model sale success develop genet test across tumor
type becom routin believ infigratinib could gener global sale
page
page
fiscal year end statesfgfr fusion cancercanc solid cancer tumor patient fgfr fusion solid tumor tumor fgfr cancer patient metastat fgfr fusion solid tumor fgfr fusion metastat solid tumor fgfr fusion metastat solid tumor fusion cca patient treat us launchidentifi fgfr fusion metastat solid tumor patient treat identifi fgfr fusion metastat solid tumor durat treatment price per per patient us fgfr fusion solid tumor sale stateseu launchinfigratinib ex-u fgfr fusion solid tumor sale worldwidetot infigratinib ww fgfr fusion solid tumor sale world-wide across indicationstot infigratinib ww sale achondroplasia
achondroplasia ach common type dwarfism character
disproportion short statur rhizomel proxim end limb shorten
limit height feet addit short statur ach patient carri signific comorbid
narrow hole skull spinal cord pass spinal stenosi spinal
straighten bow leg order improv qualiti life featur disord
appar birth allow easi post-nat diagnosi occur rate
live birth make larg orphan popul world-wide preval
ach autosom domin disord pure driven gain-of-funct gof mutat
gene mutat slightli elev basal tyrosin kinas activ
receptor rate fold wildtyp level result tonic activ
downstream signal pathway includ canon mapk wnt/-catenin
plc constant stimul pathway lead imbal cartilag cell
chondrocyt prolifer differenti growth plate lead variou
phenotyp characterist ach exhibit
page
biolog fgfr signal cascad regard chondrocyt fairli well understood
hyper-activ believ respons ach case found
gof mice develop dwarf phenotyp convers full impair
signal knockout mice exhibit bone overgrowth
studi well other literatur state chondrocyt differenti regul mapk
signal control chondrocyt prolifer suppress
activ fgfr signal target overal studi defin clear associ
fgfr signal ach etiolog
given causal role aberr gof signal ach bridgebio believ infigratinib
potenti exhibit disease-modifi potenti directli bind pathogen sourc
shut multipl signal cascad exhibit
infigratinib directli bind potenti block signal cascad
lead downregul chondrocyt prolifer chondrocyt hypertrophi
import bone growth occur ach addit also known
pathogen signal ach via downstream mapk activ
inde infigratinib shown inhibit hyperact canon mapk
signal human cartilag cell deriv achondroplasia patient inhibit
shown restor chondrocyt prolifer demonstr stat pathway downregul
improv chondrocyt hypertrophi demonstr mapk downregul
vitro studi suggest infigratinib improv biomark relat two hallmark
ach result impair key downstream signal mechan fgfr
mous model includ gof ach mutation-contain transgen
mice gener studi ach lab mice recapitul
human disord numer way includ short statur macrocephali prognat fuse
synchondros foramen magnum defect model day infigratinib
page
treatment demonstr improv across numer manifest diseas includ
long bone respons foramen magnum defect degre spinal stenosi compar
untreat mice see exhibit note preclin studi
util subcutan dose infigratinib qed pursu oral dose
strategi clinic mind mous pk bridg studi conduct oral
dose provid equival exposur subcutan dose determin
x-ray analys reveal infigratinib-tr mice exhibit increas
femur length increas tibia length untreat mutant mice exhibit
col immunostain marker chondrocyt differenti demonstr increas
bone growth activ hypertroph zone growth plate infigratinib-tr mutant mice
result suggest infigratinib therapi could lead increas height proportion
ach patient also exhibit axial skeleton defect effect infigratinib therapi spine
skull evalu infigratinib treatment afford increas foramen magnum area
increas anterior-posterior skull length rel untreat mutant mice exhibit
page
importantli infigratinib compound develop ach shown posit
effect foramen magnum area prevent sever foramen magnum narrow could
lead decreas seriou correct surgeri patient
addit potenti infigratinib therapi improv spinal stenosi evalu
increas length increas disc width observ exhibit
compani believ result may lead decreas spinal stenosi therefor
also reduc need patient undergo surgeri
overal data suggest infigratinib penetr cartilag bone
improv skelet phenotyp mutant mice via inhibitori action
compani continu studi infigratinib effect perk signal model
page
infigratinib first tki evalu ach therapeut strategi ach includ
administr c-natriuret peptid analogu biomarin vosoritid ascendi
meclozin amongst other agent demonstr improv
model except theracon demonstr efficaci
mice note improv observ infigratinib appear fold higher
therapi develop exhibit
qed believ infigratinib like efficaci agent develop
infigratinib modul pathway affect chondrocyt prolifer
hypertrophi directli bind driver diseas rather modifi bystand
signal cascad inde cnp dampen pathway alter chondrocyt
prolifer infigratinib small molecul effici reach growth plate
dysfunct chondrocyt locat less clear therapi includ
theracon could experi diffus issu similar
antibodi whose ach program discontinu lack efficaci
june biomarin releas initi efficaci data dose-find phase ii trial
evalu vosoritid ach patient patient mid g/kg qd high
g/kg qd dose cohort demonstr mean increas annual growth veloc
respect compar natur histori baselin growth veloc
biomarin continu monitor patient g/kg qd dose group found patient
experienc sustain growth veloc year follow-up exhibit track
nice report averag growth veloc normal child cm/year inde
month post initi dose patient experienc cm increas baselin
growth veloc would predict untreat state
page
note biomarin find dose respons phase ii trial could suggest
vosoritid reach maxim therapeut potenti local growth plate penetr
regardless believ data provid proof-of-concept modifi known
pathophysiolog ach result promis outcom patient biomarin current
conduct pivot phase trial enrol patient age year old
set report data compani also evalu vosoritid phase ii
trial recruit younger patient month year old
qed plan launch proof-of-concept phase i/ii studi ach patient year qed
current conduct final preclin toxic studi infigratinib highly-engag
fda clinic studi design compani believ enrol patient
year old rang similar vosoritid trial qed anticip rapid proof-of-concept
biomark col correl long bone growth evalu earli
cours treatment along long-term measur includ growth veloc notabl
qed anticip larg therapeut index given dose administ ach
patient lower dose use oncolog patient significantli lower
lowest dose hyperphosphatemia observ importantli infigratinib known
safeti profil adult treat variou oncolog set includ patient
oncolog dose longer year
qed competitor like report pivot proof-of-concept clinic data phase ii
data infigratinib read mid/lat addit biomarin vosoritid readout
describ phase ii data ascendi transcon theracon
report mid/lat data readout could occur infigratinib
qed believ conveni oral medic competitor dose subcutan
potenti increas efficaci directli target receptor potenti
provid great benefit patient less burden patient famili
page
baselin agv cm/year mean agv cohort year old believ
achondroplasia driven mutat us approxim
achondroplasia patient howev patient open growth plate less
year age elig treatment make total address popul around
around patient preval popul current achondroplasia patient
treatment option assum success clinic develop assum launch
us assum list price g/n price increas per year base
compar lower-pric orphan drug includ strensiq orkambi
cablivi importantli note infigratinib ach launch separ
brand oncolog product much lower dose well formul
model penetr upon launch number reach due potenti
best-in-class efficaci conveni dose result us sale addit
view ex-u address popul signific approxim
patient world-wide assum launch ex-u one year later assum discount us
price result sale total model infigratinib sale eclips
time-frame qed ip late infigratinib ach
beyond ach aberr fgfr signal associ tumor-induc osteomalacia
rare paraneoplast syndrom case report literatur
diseas fibroblast growth factor overproduc tumor case
case gene fusion found drive overproduct
character bone pain bone fractur muscl weak
current qed run phase ii trial collabor nih enrol
patient date two patient treat infigratinib respons
measur reduct phosphat level decreas normal level
qed believ discuss fda regard registr trial warrant
respons rate remain
page
fiscal year end statesachondroplasiaachondroplasia achondroplasia achondroplasia launchachondroplasia patient treat infigratinib treatabl achondroplasia price per patient achondroplasia us sale statesex-u launchinfigratinib achondroplasia ex-u sale achondroplasia ww sale ttr amyloidosi
transthyretin ttr natur occur protein produc liver act
transport retinol thyroid hormon thyroxin blood ttr protein exist
stabl tetram potenti destabil individu protein monom
transthyretin amyloidosi attr occur monom clump togeth amyloid
damag tissu deposit form attr inherit mutant
other caus natur age process wild-typ wt two main type
attr cardiomyopathi affect heart polyneuropathi affect peripher
attr cardiomyopathi attr-cm patient gener present heart failur
preserv eject fraction hf-pef complic pathophysiolog heart
classic heart failur instead hf-pef patient experi ventricular
reserv abnorm lead reduc fill reduc eject blood volum
heart result patient experi increas heart rate heart mechan
adapt chang sinc heart failur attr-cm patient due explicit
chang heart contractil convent heart failur therapi ace inhibitor calcium
channel blocker beta blocker treat heart contractil suitabl
patient howev recent approv pfizer vyndaqel tafamidi attr-cm
abl treat protein misfold disord via select stabil ttr
tetram refer patient exhibit one two type attr-cm
wild type-cm attrwt-cm character ttr tetram destabil
result natur age process sometim call senil system
amyloidosi ssa attrwt-cm like affect upward individu
world-wide major undiagnos
 mutant-cm attrm-cm result genetically-inherit mutat ttr
lead tetram destabil often call famili amyloid
cardiomyopathi fac mutant ttr monom plaqu also deposit heart
lead heart failur mechan attrwt-cm attrm-cm
estim affect individu world-wide major also
believ undiagnos
attrwt-cm attrm-cm similar late onset typic age higher
progress fatal patient median surviv year form diseas
known mutat affect ttr tetram stabil includ
publish studi suggest ttr instabl associ diseas sever
infer human genet inde greater ttr destabil correl
earlier onset diseas well increas sever diseas exampl nearli
carrier result lowest rel ttr tetram stabil develop highli
pathogen form diseas convers result high stabil
ttr tetram prevent ttr complex dissoci therefor protect attr
select mutat list least tetramer-stabil exhibit
page
note two form cardiac amyloidosi caus ttr anoth
caus light chain chain cardiac amyloidosi al-cm commonli diagnos
form system amyloidosi caus plasma antibody-produc cell produc
clonal excess light chain al amyloidosi occur excess light chain misfold
clump togeth deposit amyloid tissu heart prognosi
attr-cm gener better al amyloidosi though form diseas still
associ high mortal patient al amyloidosi chemotherapy-bas strategi
may control light chain product lower plasma cell level blood al amyloidosi
patient differenti attr-cm patient directli measur circul light chain
blood free light-chain assay help evalu likelihood diagnosi prior
biopsi monitor diseas respons chemotherapi eido exclud patient
diagnos al amyloidosi trial discuss detail later
report
diagnosi ttr amyloidosi current requir tissu biopsi histolog confirm
amyloid deposit congo red stain amyloid identifi immunohistochem
stain ttr perform distinguish variant wild-typ ttr isoelectr focus
ief electrophoresi altern use separ variant wild-typ ttr charg
reveal distinct electrophoret mobil differ variant ttr
case biopsi tissu process liquid chromatography-tandem mass spectrometri lc-
ms/m also identifi ttr variant sensit howev biopsi diagnos
present issu sampl error access expertis requir proper histolog
interpret limit though use less often non-invas test echocardiographi
strain imag cardiac magnet reson cmr electrocardiographi ecg use
place invas biopsi approach
technetium -label bone scintigraphi tracer long known local
myocardi amyloid deposit though molecular basi unknown therefor system
evalu pyrophosph pyp may suffici sensit specif
detect attr amyloid deposit heart importantli pyp scan allow
detect attr amyloidosi earli diseas progress develop
function abnorm detect via echocardiographi cmr studi
attr-cm patient compar bone scintigraphi biopsi investig shown patient
page
scan corrobor result biopsi analysi studi conclud sensit
posit scan detect cardiac attr amyloid deposit cardiac
attr amyloid therefor due non-invas natur test remark
sensit use imag techniqu slowli consid valuabl diagnost
approach attr cardiomyopathi
eido estim current patient diagnos ttr cardiomyopathi
us increas use pyp scan diagnosi could discov upward
patient importantli eido benefit launch pfizer vyndaqel patient
receiv either scan biopsi confirm attr diagnosi larger patient popul
alreadi identifi time come market
eido develop oral small molecul tablet like pfizer vyndaqel
potenti halt progress ttr amyloidosi bind stabil ttr tetram
blood activ prevent toxic accumul misfold ttr monom cardiac
tissu lead heart failur attr patient mimick naturally-occur
variant ttr gene protect genotyp describ previous
ttr thyroxine-bind channel three symmetr set small caviti call
halogen bind pocket hbp four iodin atom thyroxin bind innermost
bind pocket locat side chain
mutat protect due higher hydrophob interfac
dimer permit format strong hydrogen bond hold tetram
togeth eido meticul studi bind ttr discov
bind dimer similar manner mutat would act x-ray crystallographi
experi reveal strong inter-monom hydrogen bond dimer engag
resid pocket confirm mimicri shown exhibit
page
end last year eido report posit result phase ii trial evalu
safeti toler ttr stabil attr-cm attrm-cm attrwt-
cm patient wt mutant attr-cm patient given either placebo
either bid minimum enrol patient
mutant attr-cm variant includ
durat studi day follow-up period final
data phase ii trial demonstr almost complet stabil plasma ttr
dose test ex vivo fluoresc probe exclus fpe assay stabil
near dose peak trough day follow oral dose exhibit
fpe optic assay wherein phase shift linearli polar light observ
reflect thin film phase shift greater complex protein ttr
tetram monom destabil ttr monom
ttr stabil also confirm via blot day respons
consist across wt mutant attr-cm patient import note
achiev far higher stabil nearli ttr compar tafamidi
achiev stabil discuss later exhibit believ clinic
meaning differenti therapi upon outcom analys
tafamidi achiev roughli stabil ttr fpe assay shown exhibit
contrast diflunis shown achiev roughli stabil ttr tetram
howev nsaid contraind hf-pef heart failur altern tegsedi ioni
cover tyler van buren onpattro alnylam cover ted tenthoff work
differ mechan knock mutant ttr mttr mrna approv
use attr-pn drug achiev high knock mttr transcript
respect howev neither approv use attr-cm also import
emphas knockdown therapi treat mutant form diseas kol note
attr-cm patient wt reason kol bullish stabil
treatment attr-cm believ cardiomyopathi patient eventu
treat one prove effect phase believ market larg
enough stabil
page
posit clinic activ could indic chang serum ttr level accordingli
patient serum ttr level measur day compar within subject baselin
result exhibit report percent increas serum ttr baselin
show dose-depend increas serum ttr concentr subject compar
baselin mean increas serum ttr patient receiv
interestingli greater treatment
effect observ mutant attr patient stripe bar believ explain part
lower absolut serum ttr mutant attr-cm subject baselin serum ttr
concentr avail baselin one mg subject day one
mg one placebo subject
demonstr promis clinic activ data exhibit
analyz percent patient achiev normal rang serum ttr day
treatment shown exhibit notabl patient dose either
achiev normal serum ttr concentr day baselin
arm respect compar placebo arm
page
lead competitor vyndaqel tafamidi approv recent may approv
vyndaqel base phase result demonstr lower mortal attr-cm
patient placebo group shown exhibit kaplan-mei surviv curv
demonstr tafamidi result improv patient surviv surviv tafamidi vs
surviv placebo past month evid separ pool
treatment group curv blue line placebo red line month treatment
addit tafamidi also reduc rate cardiovascular-rel hospit
month compar placebo
though cross-studi comparison without error valu shown exhibit
direct posit indic dose led ttr concentr
serum higher result tafamidi treatment attrwt-cm patient
page
demonstr differ baselin mean serum ttr valu
respect tafamidi show averag chang serum ttr level
compani note comparison ttr level attrm-cm patient
show robust proport respons mutant patient produc higher level serum
ttr baselin wt patient howev mutant patient dose either tafamidi
increas serum ttr proportion seen wt patient
analysi serum ttr level show differenti tafamidi therefor may
potenti best-in-class
well-toler favor safeti profil clinically-import advers
event associ either dose phase healthi volunt
phase ii clinic trial attr-cm patient note tafamidi also similar safeti profil
compar placebo point overal safeti class
one recent publish studi patient wild-typ attr-cm regress analysi
serum ttr concentr surviv probabl suggest addit mg/dl
serum ttr associ reduc risk mortal eido use model predict
mortal benefit treatment incorpor phase ii trial dataset exhibit show
result compani predict analysi mortal treatment
base linear regress hanson model
page
model corrobor result phase attr-act trial tafamidi attr
cardiomyopathi increas serum ttr correl mortal
assum linear throughout model mortal rate patient predict
lower observ tafamidi increas serum ttr correl
mortal compar tafamidi data suggest increas serum ttr
indic overal benefit patient attr-cm
eido also current conduct on-going open-label extens phase ii trial attr-
cm data expect second half year purpos studi evalu
long-term safeti toler administ adult patient symptomat attr-
cm patient enrol phase ii dose well toler patient
continu particip studi base period recommend data
monitor committe dmc and/or registr follow posit result phase
result help think upcom data morbid mortal
readout phase cm discuss detail later section
compani initi phase clinic studi attr-cm patient februari
attribute-cm design trial shown exhibit
page
patient diagnos attr-cm mutant attr neg light chain
amyloidosi scan expect enrol studi receiv either
capsul twice daili placebo twice daili compani believ
readili achiev year enrol phase ii complet enrol
month dose select due margin improv serum ttr
concentr dose observ phase ii achiev without
increas risk safeti toler
part chang month compar treatment placebo group
potenti registr endpoint test simpl sub-maxim exercis test
evalu aerob capac endur patient walk around cours comfort
speed minut demonstr measur treatment benefit heart failur
copd primari pulmonari hypertens among mani diseas test use wide
attr-cm center includ phase ii evalu attr-cm
patient short-term primari endpoint day howev compani includ
primari outcom phase attribute-cm studi registr
shown treatment-respons endpoint attr-cm patient phase
attr-act studi tafamidi earli month start therapi exhibit
studi walk distanc tafamidis-tr patient blue line improv
placebo meter differ first observ month black line data
demonstr tafamidi achiev chang endur aerob activ cm patient
believ clinic meaning demonstr improv patient
heart function endpoint attribute-cm like facilit cross-trial comparison
tafamidi
page
part studi continu anoth month total month total
number death frequenc cardiovascular cv -relat hospit evalu
treatment control group primari outcom attr-act
phase trial tafamidi attr-cm part studi remain blind
restrict usag approv indic therapi tafamidi get remov
manag note part rational remov restrict base time
tafamidi may becom avail euthi way patient wont drop studi
take tafamidi instead part end evalu patient may enter open-
label extens receiv twice daili
design attribute-cm provid opportun near-term regulatori approv
base allow compani opportun trial expand label
includ mortal morbid base readout howev manag believ
suffici approv receiv clear guidanc fda
ema approv like month long observ detriment mortal
believ entir possibl given safeti data collect date addit
manag admit may difficult gain support payer take
convinc time point key show long-term differenti
tafamidi way use inform payor
worth note compani expect concomit use tafamidi treatment part
impact overal surviv comparison previous mention
treatment lag mortal seen attr-act tafamidi howev impact expect
comparison cv hospit separ month tafamidi
compani adjust power accordingli patient power
mortal hospit endpoint part power first ensur signific result
analysi all-caus mortal cardiovascular hospit exactli
done analysi arm attr-act studi tafamidi
compani power least good result versu placebo seen
page
attr-act number appli part allow enough power
cover robust treatment effect meter walk distanc
placebo due power compani note still possibl gain approv even
treatment effect wors seen tafamidi meter alpha split
accord negoti fda leav part power reach valu less
remain alpha appli part
one secondari outcom kansa citi cardiomyopathi questionnair month
questionnair develop measur health statu health-rel qualiti life
subject heart failur includ heart failur symptom impact qualiti life
also includ tafamid phase ii trial major patient rate
diseas either unchang improv respons month treatment averag
declin point secondari measur includ serum ttr
concentr evalu ttr stabil day month similar phase
eido began commerci prepar upon initi phase studi compani
begun patient research kol develop plan engag patient advocaci group
gain understand patient issu data alreadi collect understand diseas
preval use diagnosi rate look patient popul heart failur
preserv eject fraction seen diseas current diagnos goal
rais attr awar improv patient identif especi among high-risk popul
continu engag physician patient alik commerci plan
place includ full sale market market access capabl eido also gather
evid support preliminari discuss global reimburs bodi commerci
plan seen exhibit despit tafamidi presenc believ possibl eido
success launch attr-cm plan place given potenti product superior
larg patient popul
us patient heart failur preserv eject fraction hf-pef
diseas driven ttr attr-cm approxim
current diagnos expect grow significantli time on-going vyndaqel
launch drive use pyp scan accuraci detect myocardi
amyloid diagnosi continu develop estim current
page
diagnos attr-cm patient approach could prove
conserv diagnos patient us estim captur
like also conserv assum price
per year us well per year list price vyndaqel
consid previous mention pivot trial timelin assum approv
launch sale gener ex-u similar dynam play
patient hf-pef lower price model sale
time total global consider
attr polyneuropathi attr-pn occur attr affect nervou system also
known famili amyloid polyneuropathi fap attr-pn commonli impact patient
sensat eventu abil move beyond physic impair may also impair
proper function digest system caus diarrhea constip attr-pn affect
individu world-wide primarili eu japan almost exclus
caus inherit mutat variant ttr age onset attr-pn usual
age year old diseas progress fatal patient median
surviv diseas typic year still longer cm
tegsedi onpattro prescrib adult attr patient stage stage
polyneuropathi patient stage polyneuropathi display mild symptom mostli sensori
effect patient maintain function lower limb stage symptom moder
lower limb function affect due nerv damag caus amyloid deposit patient
may requir walk assist tegsedi onpattro success stop neurolog
injuri reduc ttr level kol note might slightli better signal
sensori improv time onpattro possibl due longer trial durat moreov
kol stress efficaci depend trial measur note tegsedi
onpattro trial differ size durat drug met primari co-endpoint
page
fiscal year end statespreval hf-pef patient attr cardiomyopathi patient hf-pef attr-cm patient attr cardiomyopathi launch treat attr-cm patient diagnos attr cardiomyopathi patient price per patient us sale ww hf-pef patient attr cardiomyopathi patient hf-pef attr-cm patient attr cardiomyopathi launch treat attr-cm patient diagnos attr cardiomyopathi patient price per patient eu sale ww ww sale
modifi neuropathi impair score determin progress nerv
injuri base neurologist assess variou deficit tegsedi-tr patient
demonstr improv time vs onpattro addit onpattro-tr
patient vs tegsedi-tr patient improv norfolk qualiti life score
compar baselin
tegsedi black box warn thrombocytopenia rem program optim
believ ioni need eas barrier prescrib physician kol note onpattro
without potenti risk extravas drug infus outsid vein infus site
reaction requir prophylact steroid dose concern administ
patient cardiac involv given cardiac relat death trial
vyndaqel shown achiev short-term delay peripher neurolog impair
stage howev studi show prevent progress nerv
damag major adult patient reason approv ema
us treatment attr-pn also recal data gener
ago dose much lower current formul market
yet test attr-pn howev due similar ttr destabil
diseas mechan posit data observ date phase ii cm compani
expect initi phase clinic trial treatment attr-pn end
data expect trial posit believ plenti whitespac
indic
base estim ioni assum attr-pn affect peopl us
europ japan within attr-pn patient popul vast major
stage diseas target popul estim similarli
conserv patient penetr price attr-cm expect launch given
current clinic trial timelin dont current model indic believ
us ex-u sale respect possibl
page
indic current pipelin compani note good start
point may treat patient pyp scan-posit ttr hf-pef-neg
addit note mutat could protect vascular diseas
well includ ischem diseas hemorrhag stroke suggest may broader
cardiovascular benefit treatment mean follow-up year publish
prospect studi particip gener popul denmark individu
genotyp two stabil variant ttr includ associ genotyp
plasma level ttr risk vascular diseas determin hazard ratio hr
calcul adjust sever factor includ age sex total cholesterol bodi mass index
hypertens diabet sever other adjust hazard ratio heterozygot
versu non-carri vascular diseas cardiovascular
diseas cerebrovascular diseas ischem cerebrovascular
diseas hemorrhag stroke bottom line hazard ratio
vascular diseas indic higher concentr circul ttr occur
individu stabil mutat associ improv cardiovascular
page
fiscal year end statespreval mutant ttr-amyloidosi patient ttr polyneuropathi patient ttr-amyloidosi stage poli patient ttr polyneuropathi launch treatabl stage polyneuropathi patient stage polyneuropathi price per patient us sale ww statespreval mutant ttr-amyloidosi patient ttr polyneuropathi patient ttr-amyloidosi stage poli patient ttr polyneuropathi launch treatabl stage polyneuropathi patient stage polyneuropathi price per patient ex-u sale ww ww sale
page
kra well-known oncogen driver cancer success target consid
holi grail oncolog remark cancer harbor kra mutat includ
lung colorect pancreat cancer altogeth repres greater
patient per year us eu patient kra mutat poor
outcom therapi hit kra mutation-posit cancer sourc desper need
bind effector molecul cell surfac receptor activ intracellular ra
transduct cascad ra famili regul activ numer signal pathway
import growth migrat differenti cell includ raf-mek-erk
akt-mtor due signific role pathway play cell ra cascad
normal tightly-control howev mutat may trigger chronic signal could lead
cancer among ra famili member mutat frequent occur kra account
ra famili mutat tumor cell becom depend signal
surviv mutat occur amino acid posit preval vari
depend tissu cancer origin importantli kra mutat found
oncogen driver cancer larg exclus mutat lung
adenocarcinoma pancreat cancer mean success inhibit strategi could
normal control physiolog condit ra protein fluctuat inact
gdp-bound activ gtp-bound state kra mutat one posit
describ protein becom stuck activ gtp-bound posit mutat
induc steric hindranc gtpase-activ protein inhibit gtp hydrolysi result
constitut activ signal cascad gtp-bound posit stabl
complex kra picomolar affin gtp mutat prevent hydrolysi gtp
gtpase tradit drug discoveri effort disrupt interact challeng
fruitless result clinician instead tri target multipl protein mapk pathway
upregul respons kra signal includ raf-mek-erk
mtor unfortun result trial target multipl pathway downstream kra
overwhelmingli disappoint kra mutation-posit cancer continu
associ poor prognosi difficulti treat kra mutation-posit
patient echo label target therapi egfr exclud patient
drug simpli dont work patient
kra undrugg oncogen due lack hydrophob bind pocket
surfac addit barrier caus highly-st kra mutant-gtp complex
prevent easily-predict high-affin small molecul bind disrupt signal recent
breakthrough made target switch region discov
region refer shokat pocket exploit next-gener kra
inhibitor cover van buren
cover raymond /wellspr uncov
function lock oncogen gdp-bound posit
potenti signific step target kra oncogen note inhibitor
address kra mutation-posit popul learn class may
read-through develop inhibitor mutat would
requir entir differ molecul due lack reactiv cystein
page
regard inhibitor class specif kol impress nm potenc
select cancer cell healthi tissu cell abil induc tumor regress
anim model kol remind us full biolog ra pathway still complet
understood activ seen anim model test particular
note inhibitor test one pancreat model
two colorect model therefor advis caution ascrib activ seen may
observ patient
gener kol expect like see differ clinic activ lung
pancreat colorect cancer patient kra driver mutat first two
progress step latter impli drug may work way
tumor type specif kol note kra mutat statu biolog much less
clear lung kra inhibit alon may enough produc respons term
singl agent efficaci kol estim inhibitor could provid respons rate
month durabl kol agre mutat allel activ
bypass kra upregul could provid escap mechan
present initi clinic data phase dose-escal
trial recruit patient locally-advanc metastat mutant solid tumor
lung cancer number small patient achiev respons one patient
convert complet respons data cutoff exhibit
addit patient achiev stabl diseas sd amount
beyond lung cancer patient kra also enrol though kra
typic founder mutat suggest target may effect
initi data suggest activ evalu patient saw
page
importantli well safeti profil larg benign grade treatment-
emerg advers event two grade event anemia diarrhea report
initi result promis durabl remain unknown longest treatment
durat current week five lung cancer patient experienc pr remain
treatment data cutoff
thera develop pan-mut kra inhibitor current conduct lead
optim effort compani pursu two approach parallel includ
binder prevent kras/cel membran associ binder trigger
degrad gtp-bound kra exhibit
page
target modal potenti bind kra mutant could allow
therapi activ patient harbor kra mutat pan-mut
kra inhibit approach attract inhibitor would retain activ patient may
develop site-specif mutat mutation-specif inhibitor inde
compani believ pan-mut kra approach could less prone treatment-resist
mutat compound target main catalyt domain kra like
inhibitor futur site-specif inhibitor class
thera built core effici capit resourc cooper research
develop agreement crada nci lawrenc livermor nation laboratori
nci compani centerpiec govern invest focu
ra call ra initi head thera scientif founder dr frank
within ra initi work conduct thera prioriti project
compani access cross-disciplin team scientist lawrenc
livermor nation laboratori compani access comput hour
perform comput chemistri power supercomput world thera
leverag resourc simul ra activ identifi refin novel drug strategi
effort nation lab led progress identifi key featur kra protein
structur reveal novel drug bind pocket discuss notabl
crada allow thera exclus licens compound develop
collabor
lead binder program thera increas cellular potenc past
two year driven sub micromolar critic well thera shown
drug candid highly-select mutant kra wildtyp kra
import provid high therapeut index clinic compani current work
page
improv inhibitor potenc across kra mutant variabl current present
addit compani identifi lead seri compound bind previous
undescrib pocket induc kra degrad drug candid select thera
pan-mut kra inhibitor program expect ind follow month later
target strategi detail
reactiv cystein residu locat hypervari region hvr tail ra
protein farnesyl transferas geranylgeranyl transferas add lipid order allow
ra protein anchor cell membran membran tether requir
convers inact kras-gdp activ kras-gtp blockad event could inhibit cancer
growth thu make attract target
thera binder aim prevent kras/cel membran associ similar principl
cover van buren tipifarnib farnesyl transferas inhibitor
inhibit mutant hra activ analog way howev tipifarnib effect kras-
driven cancer redund compensatori activ geranylgeranyl transferas
also mediat kra tether membran geranylgeranyl transferas inhibit also
evalu clinic demonstr limit success due toxic result
non-specif activ altern thera hypothes direct inhibit could prove
effect target would block membran tethering-promot activ
residu occlud activ transferas therefor prevent kra activ
molecular model perform collabor nation lab thera discov
initi binder also modifi area ra evid
contain tail fold back onto main bodi kra protein interact previous
undescrib g-domain/switch ii region near shokat pocket pocket amgn mrtx
jnj/wellspr kra inhibitor bind observ suggest
thera robust interact exist region hvr
kra structur theoret creat novel druggabl pocket thera
refer druggabl structur pocket compani hypothes
pocket may abl target stabil binder
success target forc complex remain close posit therebi prevent
kra membran process essenc tail fold back kra protein
base find describ thera develop small molecul binder
recruit addit stabil interact among pocket secur
inhibitor bind critic binder must possess right geometri electron facilit
non-coval interact area allow coval bond format identifi
drug candid satisfi aim compani screen ucsf tether librari
includ compound lead target perform desir coval
stabil bind event effort led identif posit hit
optim drug-lik thera found lead compound bind
predomin kra splice variant creat potenti select
kra ra protein includ hra exhibit
page
assay find hra open hvr
unaffect target inhibit suggest inhibitor specif toward
demonstr nra similar open hvr support specif bind
activ toward oncogen encouragingli inhibit observ two
variant indic compound pan-mut kra inhibit
compani also observ inhibit caus dose-depend decreas
intracellular kra exhibit believ due binder coval bind
evidenc western blot binder treatment specif reduc
level leav kra unaffect experi suggest
binder stabil kra hvr toxic kras-depend cell
compani believ kra level reduc result increas cytosol vesicl
recycl proteasome-medi degrad kra
page
thera achiev select mutant kra
wildtyp sensit variant exhibit
compani current work optim compound demonstr robust
activ across kra mutant
uniqu residu isoform conserv form mutant
kra highlight resid pocket form result
hvr fold onto g-domain/switch ii region kra molecular model experi
suggest exist druggabl pocket requir concomit bind
therefor present distinct drug discoveri opportun area locat g-
domain next shokat pocket expos kra activ gtp-bound state
import mutant kra larg exist activ state ratio
inact gdp-bound protein comparison site expos inact gdp-
bound state mean inhibitor must bind moment mutant kra
thera current work seri compound non-coval interact
previous discuss effort enhanc thera access supercomput
model structur biolog kra area resourc allow compani
explor complex molecular dynam electrostat forc field enabl structur
activ relationship orient analysi creat lead compound align bind
pocket tightli
date initi iter binder label figur shown specif
reduct phospho-akt suggest bind critic effector kra
page
previous implic drive ras-medi tumorigenesi mainten
abil inhibit effector function ra potenti signific thera believ
first put inhibitor effector bind kra also recent discov
disrupt interact induc tumor regress egfr-mut driven
lung cancer model due novel natur target ra compani aggress
pursu mechan
contrast binder appear stabil ra binder appear de-
stabil ra seen decreas ra melt temperatur exhibit
page
compani believ de-stabil ra state unabl bind could facilit
ubiquitin common phenomenon protein unabl bind target partner
cytosol mechan thu allow ra degrad result elimin
pan-mut strategi develop thera see immedi
competit cover tenthoff merck uncov co-
develop mrna vaccin target four common kra
mutat vaccin design induc neoantigen respons could allow t-cell
attack tumor harbor kra mutat candid current preclin develop
howev vaccin requir specif kra allel hla-restrict vaccin may
address kras-mut patient addit astrazeneca azn uncov licens
cover van buren rnai technolog
origin develop ioni target rna sequenc kra inhibit protein product
test phase trial nsclc program discontinu due
lack activ kol note antisens cancer therapi larg
unsuccess deliveri lack oncogen signal shutdown key limit factor
pan-kra mutant approach attract given larg number potenti patient
reflect recent investor excit kra inhibitor class drug
develop mirati though mention inhibitor address
kra mutation-posit popul thera potenti address
kra etc specif market build exhibit
estim us ex-u sale kra mutation-posit nsclc pancreat cancer
colorect cancer kra mutat also found vari preval other cancer
includ endometri thyroid stomach bladder melanoma head neck squamou cell
carcinoma multipl myeloma estim launch kra mutation-posit
cancer us quickli grow sale ex-u model bbp-
launch one year later model sale time frame
page
success develop believ peak sale could surpass
make one largest drug pharmaceut industri
page
fiscal year end cell lung cancerunit statesmetastat nsclc nsclc patient kra metastat nsclc launchmetastat kra nsclc patient treat metastat nsclc patient kra durat treatment price per patient us kra nsclc sale stateseu ex-u kra nsclc sale cancerunit statesmetastat pancreat cancer pancreat cancer patient kra metastat pancreat cancer launchmetastat kra pancreat cancer patient treat metastat pancreat cancer patient kra durat treatment price per patient us kra pancreat cancer sale stateseu ex-u kra pancreat cancer sale cancerunit statesmetastat colorect cancer patient kra metastat launchmetastat kra patient treat metastat patient kra durat treatment price per patient us kra sale stateseu ex-u kra sale worldwidetot ww kra cancer sale debilit
part normal hypothalamic-pituitary-adren hpa axi adren cortex produc
three class hormon includ mineralocorticoid aldosteron maintain
bodi salt water level glucocorticoid cortisol sever adren androgen
normal hpa axi allow homeostat increas cortisol time stress
product adrenocorticotrop hormon acth subsequ increas
hydroxyprogesteron lead increas androgen product well
elev cortisol product activ enzym
congenit adren hyperplasia rare inherit autosom recess disord
debilit life-threaten case caus inactiv mutat
gene account product defici send
cortisol/acth homeostasi disarray uninhibit acth primarili direct androgen
product render patient unabl produc cortisol aldosteron
produc excess testosteron hpa axi depict exhibit normal
product cortisol express well product androgen caus
loss highlight red
preval estim us eu diagnosi earli
routin newborn screen defici perform everi us state
page
clear genotype-phenotyp relationship enzym activ patient
clinic manifest specif patient lack product diseas
symptom sever exhibit show level peak morn cortisol variou genotyp
within patient sever symptom salt-wast diseas express normal
level make roughli patient defici patient
express higher level chanc experienc adren crisi dramat reduc
fact natur histori studi conclud threshold level normal express
ug/dl protein may prevent adren crisi note analog factor
replac requir gene therapi revers phenotyp hemophilia patient
non-class mutat result normal level achiev higher-than-
threshold level cortisol avoid adren crisi shown product
normal wild type level diseas symptom mild mutat lead
normal level yet achiev peak cortisol level wild type patient
interestingli wild type product patient asymptomat
base genotype-phenotyp studi compani believ restor
wt enzym level may suffici prevent adren crisi
diseas lead poor qualiti life mar fear adren crisi life-
threaten condit brought acut cortisol defici adren crisi may caus
physic stress infect dehydr trauma surgeri adren pituitari injuri
prematur cessat steroid therapi femal patient also experi viril
develop characterist associ male hormon overproduct
testosteron given diseas burden patient mortal three time higher healthi
peer patient also three-fold increas risk cardiovascular metabol
current standard care steroid offer margin benefit patient carri seriou
toxic relat long-term use steroid supplement effect patient
improv basal cortisol suppress acth secret reduc excess
androgen product howev lack specif may lead over-dos potenti caus
cush diseas sever bone loss adult overdos potenti
page
danger life-threaten children well children experi
supraphysiolog steroid dose high percentil children
develop hypertens ad complic steroid supplement under-dos may
lead overproduct androgen associ abnorm sexual develop
scenario femal develop hirsut masculin genitalia fertil
issu male develop testicular adren rest tumor lead gonad dysfunct
pain infertil clear statist patient rare experi safe
effect middl ground androgen product control side effect
addit current standard care fairli inadequ patient experi
increas risk cardiovascular/metabol diseas unpredict risk lethal adren crise
steroid often avail emerg set prove fatal due risk
great need effect therapi particular one restor
adrena develop preclin adeno-associ gene therapi
treatment design allow patient achiev homeostat control adren
hormon treat root caus diseas defici express
transgen replac enzym transduc adren cortex cell produc
replac essenti enzym restor activ natur hormon
steroid cycl increas aldosteron cortisol product reduc testosteron
therefor risk adren crisi compani hope enter clinic therapi
file ind date adrena complet sever preclin studi
intraven administ mice non-human primat nhp establish proof
concept therapi result discuss
bridgebio partner paragon bioservic recent purchas
cover sean wieland may effici support clinic commerci
cgmp suppli gene therapi program partnership allow bridg scale
research grade product commerci grade one top provid aav product
capabl prefer partner bridg prioriti access develop manufactur
need addit partnership compani also build intern process develop
analyt establish control process decis product character assay
compani believ intern develop allow control oversight
acceler clinic product aav gene therapi program
knockout ko mous model character decreas bodi weight
four-fold increas progesteron level impair stress respons increas express
gene involv acth signal genet delet lethal steroid supplement
perdomini et al publish studi investig adren tropism
whether treatment vector correct phenotyp biochem alter
ko mice determin specif adren tropism multipl aav serotyp includ
group found serotyp gener robust neutral antibodi respons
other ideal antibodi could lead elimin drug
within bodi produc lowest neutral respons show strongest
tropism adren tissu basi select deliv compani gene
therapi vector also current use human gene therapi clinic trial
testament safeti vivo
page
select serotyp vector express control promot
drive high level gene express inject express vector led
increas bodi weight ko mice shown exhibit
week post-inject aav ko mice treat grey bar
display increas bodi weight week post-inject week
post-inject compar sham-treat ko mice black bar wild type
mice control untreat group maintain normal bodi weight level throughout
cours studi white bar
previous mention ko mice histor character four-fold
increas progesteron level wild type mice shown exhibit ko mice
inject sham vector black bar approxim increas urinari
progesteron concentr untreat wt mice white bar everi time point
measur vector induc dramat decreas urinari progesteron
correct complet gray bar
import note progesteron level still remain approxim two-fold higher
week post-inject vector-tr ko mice gray bar compar
untreat wt mice white bar due lack durabl manag state
studi perform find optim dose durabl respons
page
compani consult kol suggest adren gland involut may play role
durabl respons involut process cell adren gland die
lead larg reduct mass adren gland kol note
gland mass lost birth week age human mice involut
complet week birth kol also note specif adren gland
gene therapi approach would unaffect process therefor compani
express age involut would primari consider dose strategi
compani began plan experi non-human primat nhp gain better
understand durabl vivo optim dose strategi ideal
promot select compar direct intra-adren inject intraven iv
administr compani saw even distribut across adren gland iv
strategi moreov adrena consid iv approach less riski due smaller chanc
adren infect result local inject sometim seen local steroid
inject compani also found constitut rather adrenal-specif
promot better approach allow lower viral dose therefor reduc risk
immun destruct viru lead greater chanc efficaci
adrena ran studi assess differ dose
week non-human primat nhp highest dose
analyz analyz week genom copi vgc rna level
measur track durabl aav gene express adren cortex data
time point yet avail data found exhibit
page
though shown small declin vgc week adren
compani note aav serotyp unpack differ rate take longest
week peak week therefor expect mrna level increas
week follow small declin vgc vector unpack week
accordingli rna level increas dramat nhp
week dose howev highest express seen highest dosag
week blue previous mention data current avail highest
dose overal data suggest signific transduct adren suffici
vector genom count mrna express three month follow singl dose
data key assess durabl move forward see soon
havent seen data compani note durabl still observ
compani pursu preclin develop explor
relationship phenotyp correct rna level mice order establish
minim effect dose done assess structur function
adren medulla cortex overal frailti stress level assess
previous addit lot manufactur compani
use initi glp toxic studi specif studi look whether
steward pathway may mediat hypertens complic
put adrena track file ind clinic proof concept data expect
first trial plan dose rang escal phase
like adult patient year age compani would like eventu expand
pediatr dose arm well compani note aav program biomarin
page
therapi project timelin year first-in-human studi top-line data
readout pivot trial similar timelin expect
believ adrena gene therapi approach like make meaning
differ patient competitor program neurocrin cover
david amsellem receptor antagonist recal march neurocrin
demonstr reduct baselin acth level
patient treat phase ii adult patient studi includ
sequential-cohort design nbi-dos cohort dose administ three cohort
consecut day meaning reduct also observ androstenedion
biomark drug well-toler accord david amsellam key question
regard neurocrin pivot studi extent fda want see clinic
endpoint specif whether clinic endpoint steroid burden part
primari outcom assess
similar strategi also develop small molecul block
receptor pituitari gland tildacerfont test phase ii trial
includ patient uncontrol classic patient cohort receiv two week
treatment three dose day qd total six week treatment cohort
saw improv androstenedion patient acth
improv patient eight patient cohort treat week
mg twice per day bid improv androstenedion demonstr patient
acth level improv patient
respect howev compani provid detail extent
antagonist work attenu overproduct product
adren androgen agent address root caus like still requir
life-long steroid supplement previous discuss steroid treatment offer margin
benefit patient may caus seriou toxic use long-term fact knowledg
shown data steroid reduct yet
addit develop potent inhibitor
enzym catalyz transform free cholesterol cholesterol ester cholesterol
ester serv substrat reservoir steroid biosynthesi goal inhibit
process may result reduc androgen product found adren tropism
preclin studi current test phase ii clinic trial studi assess
efficaci safeti addit corticosteroid patient studi
design determin effect dose rang dose primari endpoint investig
adren steroid product measur serum concentr howev like
antagonist strategi also address root caus diseas bottom
line drug gene therapi give opportun
dramat reduc elimin steroid supplement goal program
first exactli
mutat gene lead reduct enzym account
case potenti larg address popul gene therapi
patient us eu estim us ex-u sale incid
preval patient popul assum patient
express antibodi estim launch
us assum sale ex-u model launch one year later
page
model sale time frame success develop believ
could gener global sale also note bridgebio
ownership stake adrena march
page
fiscal year end statescongenit adren hyperplasia preval populationcongenit adren hyperplasia preval patient mutat patient mutat patient mutat untreat patient mutat us launch patient mutat treat current untreat patient mutat price per patient us sale statesex-u ex-u sale statescongenit adren hyperplasia incid popul incid patient mutat patient mutat patient mutat launch patient mutat treat elig patient mutat price per patient us sale statesex-u ex-u sale ww sale molybdenum
molybdenum cofactor defici mocd metabol diseas occur due genet
mutat prevent patient express molybdenum cofactor moco moco
import regul three key metabol enzym prevent damag central nervou
system includ sulfit oxidas xanthin oxidoreductas aldehyd
oxidas synthesi moco occur respons convers guanosin triphosph
gtp cyclic pyranopterin monophosph cpmp patient mocd type mutat
gene prevent gtp convers disrupt cpmp synthesi subsequ
decreas sulfit oxidas activ result increas sulfit level lead accumul
highli toxic glutam analog s-sulfocystein ssc lead sever neurolog damag
schemat diseas mechan found exhibit
mocd type account mocd patient estim affect children
world-wide though origin believ diseas underdiagnos preval could
much higher mocd sever progress character heterogen
neurolog symptom includ seizur feed difficulti current patient
estim life expect year patient homozyg mocd type
diseas present earli one day birth heterozyg individu case
common homozygot may present symptom later earli childhood genotyp
typic confirm upon diagnosi along blood urin metabolit analysi quantifi
extent patient neurolog damag target treatment current avail
physician offer palli care includ anti-convuls therapi
page
origin believ patient identifi diseas awar patient screen
effort increas compani analyz data sever compani
develop first-in-class therapi rare diseas includ sanofi sni uncov
notic diagnost subsequ treatment rate rare diseas doubl
drug came market observ pomp gaucher fabri diseas shown
exhibit
accordingli origin undertak effort increas earli diagnosi mocd type
develop rapid bedsid test creation educ awar patient
support program base extens consult kol compani also speak
provid diagnost panel includ mocd type patient screen assay
effort import consid compani clinic program go forward
manag believ mocd sever underdiagnos path forward need creat
enabl robust market opportun
origin develop iv-administ synthet cpmp design restor moco
product reduc toxic sulfit reduc brain damag type mocd patient shown
exhibit promot moco biosynthesi lead downstream activ
sulfit oxidas therefor potenti reduc toxic caus build-up ssc
page
june origin enter asset purchas agreement alexion cover
chri raymond acquir alexion right includ patent agreement
payment also paid upon achiev develop mileston
upon achiev sale mileston royalti low- mid-
teen net sale addit compani purchas prioriti review voucher prv
alexion receiv payment
data phase ii phase ii/iii demonstr promis activ exhibit
detail achiev meaning develop function improv
separ treat patient histor control
page
note patient treat abl roll sit upright self-
support manner patient ambulatori mileston
typic seen mocd type patient import note genotyp
three patient achiev ambulatori control associ sever phenotyp
histor control match histor control die either day year age
highlight extent rescu sever manifest diseas
believ valu proposit similar new spinal muscular atrophi sma
impress patient treat aliv march blue line
natur histori patient match genotyp die age year black line
page
histori mocd patient
first time durabl improv surviv function neurolog outcom
seen mocd patient import compani seek approv
current studi on-going phase ii ii/iii clinic trial compani plan
submit roll nda launch product base
posit respons seen date drug clean safeti profil believ approv like
addit expect approv expedit compani receiv
breakthrough design manag note receiv posit
feedback fda thu far compani like seek prioriti review us
seek meet ema near-term given sever mocd diseas lack
avail treatment compani believ meaning demand
world-wide addit increas patient diagnosi compani plan expand treatment
effort includ heterozygot increas overal opportun mocd
page
dystroph epidermolysi bullosa deb devast rare genet skin diseas manifest
vari level sever preval deb estim per million
patient us eu deb sever form known
recess deb rdeb affect sever tissu organ patient demonstr extens
skin blister wound scar sever impact digest system includ esophagu
gastrointestin tract corneal eros dystrophi loss nail joint contractur
pseudosyndactyli mitten deform hand feet patient often develop
aggress squamou cell carcinoma major contributor mortal cumul
mortal deb patient age
approv target therapi deb instead current standard care deb
patient larg palli result signific burden live patient
famili current treatment consist bathing/wound dress open wound topic
antisept antibiot infect analges nsaid opioid anti-anxieti drug
pain manag nutrient supplement g-tube feed due nutrit compromis
surgeri pseudosyndactyli esophag strictur
pathophysiolog deb well understood sever associ degre collagen
type vii protein level critic junction protein form anchor fibril af
secur associ epiderm basement membran underli papillari
af present mani tissu organ especi affect rdeb patient includ
skin oral mucosa esophagu cornea chorioamnion cervix anal canal mutat within
gene exhibit deb rdeb patient lead littl level
page
function result deb rdeb patient demonstr impair stabil epitheli
tissu result numer symptom
phoenix tissu repair ptr develop intraven deliv
recombin treat system manifest deb receiv
orphan drug design fda ema treatment deb fast track
design fda treatment deb ptr believ intravenously-deliv
local basement membran form af compens
lack function protein deb patient success administr could restor
function epithelium allevi symptom diseas exhibit
ptr develop chines hamster ovari cho cell line produc preclin
clinic use preclin studi iv-administ found distribut
basement membran skin knockout mice per exhibit
page
studi detect variou target skin tissu immunofluoresc infus
found local dermal-epiderm junction littl
detect area saline-tr mice
infus observ promot format af evidenc
closur space epiderm dermal layer exhibit
ptr believ restor af promot heal improv surviv rdeb inde
preclin studi compani found singl infus neonat rdeb mice
associ statist signific improv surviv compar vehicle-tr
control data shown base result strong underli scientif rational
ptr believ disease-modifi potenti revers deb
phenotyp patient
previous develop shire/lotu tissu repair tak uncov
invest improv manufactur protocol howev cours
develop shire found immun complex deposit event caus local
inflammatori respons includ releas inflammatori cytokin enzym reactiv
oxygen speci decid shutter program
ptr believ immun complex deposit uncharacterist effect like
result high dose conduct seri safeti studi inde singl
infus dose toxic studi conduct rodent non-human primat nhp
shown well-toler repeat dose rat toxicolog studi two
repeat-dos intraven toxicolog studi nhp conduct repeat-dos
page
studi ptr observ histopatholog result confirm format immun complex
deposit base result ptr dose low slow order establish no-
observed-adverse-effect-level noael highest dose immun complex
deposit observ noael determin mg/kg nhp use
inform start dose phase i/ii clinic trial describ extens studi bbp-
test anim month safeti concern pd studi bbp-
detect four week tissu rdeb mice half-lif serum
rang one five hour mice rat nhp base result ptr believ
immun complex deposit concern address
ptr current enrol phase i/ii proof-of-concept trial adult patient rdeb
sever form deb studi random dose-escal trial treat patient
dose vehicl cours week follow follow-
period exhibit
primari endpoint studi includ safeti toler secondari endpoint
design show proof-of-concept includ chang skin biopsi anchor
fibril chang heal chronic wound patient report outcom includ itch
quality-of-lif assess pk respect wound heal endpoint fda
believ wound closur meaning outcom result anticip
avail
first patient trial dose compani dose two patient
importantli bridg observ immunogen either patient studi
proceed enrol patient next dose cohort cohort compani believ like
therapeut dose
numer therapi develop rdeb patient ptr may
truli disease-modifi systemically-act agent therapi develop deb/rdeb
uncov epiderm sheet
graft consist ex vivo autolog gene-correct keratinocyt phase i/ii
clinic trial complet show closur suggest could
page
help treat larg and/or sever skin wound howev product requir surgeri
appli logist complic manufactur transport patient may need
uncov off-the-shelf allogen
gene therapi current phase i/ii clinic trial
product conveni appli wound applic alreadi damag
skin preclud prophylact use topic agent may abl
penetr intact stratum corneum addit downsid requir on-sit
treatment due viral vector larg negat conveni factor
fibrocel fcsc uncov lentivirus-bas gene
therapi complet phase i/ii test show wound closur
target lesion dermal fibroblast collect patient cultur
genet modifi provid high level inject local
affect area patient howev potenti concern genom integr
associ lentivir use
wing topic rna oligonucleotid therapi deb
exon gene result product shorten
function protein product current phase i/ii test requir patient
harbor exon mutat
though product may provid relief patient import note
product treat local skin wound expect system benefit
patient ptr believ superior therapi list
address system viscer manifest diseas may use prophylact
treatment conveni dose schedul potenti bi-weekli month
page
venou malform vm larg disorgan vein caus signific morbid
due pain bleed disfigur lymphat malform lm involv lymphat
channel overgrown and/or disconnect lymphat system caus lympat
leakag addit similar complic vm us eu estim
patient vm lm current standard care invas
exclus palli includ recurr laser ablat lesion surgic resect
sclerotherapi remain fda-approv therapi indic condit
phosphoinositid pathway extens studi cancer
mutat gene encod catalyt subunit known
oncogen beyond cancer mutat also found drive sever overgrowth
disord collect refer overgrowth spectrum
recent mutat tek direct upstream activ
found drive pathogen signal vm lm case exhibit
agent akt mtor inhibitor use treat vm lm neither
complet shut signal cascad associ increas signal
downstream mtor inhibit lead resolut lesion volum pain treatment larg
produc cytostat effect result regress patient
page
recent compassion use trial show oral dose inhibitor caus
profound regress vm lm sever patient studi conduct patient
mutat remark system inhibitor therapi demonstr reduct
vascular lesion patient result promis patient
option toxic concern chronic system inhibit hyperglycemia liver
enzym elev glow syndrom particularli children less sever patient
venthera develop novel inhibitor topic formul
potenti treat vm lm patholog sourc compound origin
develop astella pharma alpmi uncov compani reformul
transderm gel design local penetr skin inhibit control
manner venthera believ transderm approach may allow lower system exposur
inhibit provid suffici local inhibit allevi vm lm lesion
execut preclin clinic develop program compani routin collabor
lead formul biolog vm/lm diseas expert
comparison novarti nv uncov alpelisib fda-approv oral
inhibitor vitro studi suggest exhibit similar potenc mutant vm
patient deriv endotheli cell huvec hdmec exhibit
skin flux assay franz cell chamber skin permeabl fold greater
achiev topic rapamycin current use off-label lm vm patient
mutant mous model vm castel et al report demonstr
regress vm lesion therebi provid proof concept transderm approach exhibit
page
venthera also conduct studi character rel skin system concentr
compani observ exhibit increas concentr site
lesion compar orally-dos novarti compound exhibit
importantli compound present circulationcompar lowest
expos dose nv oral inhibitor trough
togeth data indic venthera success engin local skin
permeat maintain pharmacolog activ orally-dos inhibitor base
promis studi venthera current manufactur glp-grade quantiti
support on-going ind-en toxicolog studi compani expect file ind end
page
lm
immedi direct competitor relat topically-formul
inhibit variou compound develop includ artham
therapeut orally-dos inhibitor develop vm
arqul arql uncov miransertib orally-dos pan-akt inhibitor phase i/ii studi
proteu syndrom
page
pathophysiolog underli group inborn-error metabol thought
associ decreas coenzym coa coa intermedi disord
pantothen kinase-associ neurodegener pkan collect organ
pkan rare progress neurodegen disord onset earli life
preval patient us eu pkan
character iron deposit brain typic caus emerg diseas
symptom age mutat lead decreas pantothen
kinas pank activ result decreas coa exhibit
patient earli onset demonstr motor deficit sometim night-blind due
retin degener patient later onset late childhood/earli
adulthood present psychiatr symptom progress parkinson diseas
diagnos detect iron deposit via magnet reson imag mri
confirm detect mutat gene current
disease-modifi therapi standard care focus symptom
caus mutat enzym control amino acid metabol
result toxic aris due high concentr acetyl-coa sequestr free
coa alter mitochondri energi metabol exhibit
page
result malnutrit development delay potenti neurolog kidney
cardiovascular damag type oa includ propion acidemia pa propionyl-coa
acidemia ia isovaleryl-coa dehydrogenas glutar acidemia type ga glutaryl-
coa dehydrogenas mutat gene detect standard newborn
screen class preval incid case
us eu current standard care includ dietari restrict administr
l-carnitin glycin promot secret acetyl-coa liver transplant
none prevent long term consequ diseas
coa develop first-in-class brain-penetr modul
pantothen kinas small molecul alloster bind
increas activ subsequ increas coa product vitro studi
prevent feedback inhibit acetyl-coa propionyl-coa increas pank activ near
presenc acetyl-coa reason coa believ
address diseas character defici coa metabol
pkan compani believ increas activ
normal coa level therebi prevent diseas symptom pkan mous model
lack result reduct brain coa treatment
mg/kg/day sinc wean restor coa level brain exhibit
page
pkan mous also demonstr signific locomotor defect indic
reduct percent time move open-field test treatment regimen
significantli increas movement time though complet restor wt level
median surviv significantli prolong day roughli long
untreat pkan mice data shown
page
coa also hypothes therapi improv metabol dysfunct
observ variou compani believ increas free coa acetyl-coa may
overcom inhibit mitochondri respir caus build-up toxic metabolit
organ acid pa mous model pa administ mg/kg/day
wean increas free coa liver level similar found wildtyp mice data
shown pa mice gain weight similar rate wild-typ mice suggest
overal metabol balanc restor lastli compani found therapi
decreas ratio metric associ
repeat dose toxicolog studi dog compani lead candid led
develop corneal ulcer dose-depend manner otherwis compound
well toler signific effect observ central nervou
respiratori system day repeat-dos studi rat clean compani believ
toxic observ dog off-target species-specif develop two back-up
compound pend result ind-en work toxicolog result ind
anticip submit next year
beyond ind-rel work coa current expand preclin proof concept
studi disord coa deplet and/or sequestr includ hmg-coa lyas
pkan two compani work substrat replac therapi
uncov develop fosmetpantoten current phase trial therapi
short half-lif must dose three time day may suffici brain penetr
increas coa level privat similar product preclin
oa cover ted tenthoff file ind
treatment mma conduct preclin work treatment pa
kol suggest mrna-bas approach may work well resolv symptom
diseas given lack brain penetr hemoshear therapeut privat also two
preclin program mma pa selecta bioscienc selb uncov logicbio
uncov work gene therapi program expect submit
ind approv coa believ gene therapi may address system
diseas symptom like address manifest cover
ted tenthoff also develop synthet biotic candid pa
page
primari hyperoxaluria sever rare autosomal-recess inborn error metabol
disord caus overproduct endogen oxal result liver alanine-
glyoxyl aminotransferas agt defici lead high oxal level urin
character frequent kidney stone blood urin interstiti kidney deposit known
nephrocalcinosi preval estim us eu
diagnosi difficult symptom non-specif diseas awar amongst
physician rel low
patient present diseas symptom earli life current standard care includ
vitamin citrat supplement increas fluid intak order dilut urinari oxal
concentr though patient respons vitamin supplement
respond still unabl achiev deem safe level urinari oxal
suggest diseas control inadequ vast major patient unfortun
diseas progress larg unprevent patient progress end stage renal diseas
median year point patient high risk system calcinosi calcif
organ lead morbid death cur treatment avail
today combin liver kidney transplant
normal agt convert glyoxyl glycin safe elimin urin patient
howev agt lack result transient increas glyoxyl level
lactat dehydrogenas ldh convert glyoxyl oxal excret
urin promot format calcium oxal crystal kidney urinari tract lead
develop recurr renal damag result progress kidney diseas
context glycol oxidas go peroxisom enzym locat liver
catalyz convers glycol glyoxyl therebi potenti pathophysiolog
page
orfan believ inhibit go could reduc urinari calcium oxal format patient
prevent glyoxyl build-up compani current develop oral small
molecul design inhibit go treat sourc orfan believ alnylam
cover ted tenthoff lumasiran sirna go provid clinic proof concept
go inhibit strategi howev due high cost good potenti increas risk
long term toxic associ sirna orfan believ small molecul
approach sustain manufactur point view highli attract treatment
potent singl digit nanomolar inhibitor go exhibit good pharmacokinet
profil dog preclin mous model carri null mutat
gene demonstr reduct urinari oxal exhibit
studi mice dose day orfan believ reduct in-
line preclin data gener lumasiran kol expect reduct urinari oxal
lead reduct stone format patient initi result promis
reduct urinari oxal observ along correspond increas urinari
glycol substrat go exhibit
page
current orfan continu optim lead candid clinic candid
expect nomin taken ind-en studi importantli
fda accept reduct urinari oxal approv biomark endpoint
trial suggest orfan may abl reduc time cost potenti
approv accordingli compani explor potenti proof concept trial design
includ screen select high oxal patient
beyond orfan receiv kol feedback suggest larg portion idiopath
frequent stone former fsf may also result high level oxal could benefit
go inhibit inde mani fsf exhibit recurr kidney stone compris calcium
oxal estim preval patient us larg popul
patient amen small molecul treatment modal
competitor orfan includ rnai strategi alnylam lumasiran target go
current phase trial dicerna uncov develop dcr-phxc
rnai target ldha current phase ii/iii trial
page
netherton syndrom ns genet inflammatori skin diseas caus autosom
recess mutat serin proteas inhibitor kazal type gene
encod lekti lympho-epitheli kazal type relat inhibitor type lekti serin
proteas inhibitor express skin function inhibit kallikrein
uncheck activ result prematur shed outer skin layer call
stratum corneum due cleavag cellular adhes protein activ inflammatori
cytokin structur key epitheli barrier loss stratum corneum life-
threaten newborn due risk system sepsi sever dehydr ns also lead
chronic problem patient includ allergi infect inflamm exact preval
ns unknown estim patient us
eu current disease-modifi therapi avail ns patient
treatment limit topic relief product antibiot
literatur combin knockout found revers ns phenotyp
mice base evalu seri klk inhibitor effect shut
activ vitro human skin extract assay develop
compani follow lead most medicin chemistri team develop
topic small molecul effect replac lekti function local skin exhibit
first dual-target serin proteas inhibitor develop ns compani
believ import absenc ns observ doubl
knockout knockout mice exhibit
page
compani current test mous model ns studi posit
clinic candid nomin final ind-en studi submit ind
sever program develop ns lifemax healthcar intern corp
privat develop topic kallikrein inhibitor origin develop novarti
complet phase iia clinic trial sixera pharma privat develop
small molecul kallikrein inhibitor preclin develop outsid small molecul azitra
privat develop staphylococcu epidermi strain engin express
lekti preclin develop addit uncov
develop base topic gene therapi preclin
page
leber hereditari optic neuropathi lhon rare mitochondri diseas eye
driven mutat subunit complex electron transport chain mutat
identifi diagnost test mutat caus dysregul mitochondri oxid
phosphoryl result decreas complex byproduct includ succin
lead reduc mitochondri function subsequ impair energi product result
patient lhon develop sever loss central vision due degener retin
ganglion cell lead legal blind patient within month diseas onset
typic lhon manifest one singl eye case occur bilater roughli
patient typic young adult affect diseas us eu
annual incid rate new case treatment current avail treat
diseas except low-vis aid great need target therapi restor
mitochondri function natur vision patient lhon
fortifi develop intravitr inject succin pro-drug design
compens loss complex activ mitochondria eye by-product complex
function succin critic substrat complex ii activ compani believ
could restor downstream mitochondri energi product restor deficit lhon
chemistri program in-licens neurov nevpf uncov june
agreement includ provis bridgebio/fortifi develop select lead
compound chemistri suitabl deliveri eye neurov novel
succin pro-drug program total valu deal includ
fund initi research mileston payment single-digit royalti net sale
program lead commerci product
paper publish ehing et al collabor neurov succin
pro-drug shown overcom inhibitori effect complex small molecul inhibitor
rotenon vitro exhibit
page
experi mitochondri respir output measur use seahors
bioscienc xfe extracellular flux analyz intact platelet treat
increas mitochondri oxygen consumpt observ even presenc
rotenone-induc complex inhibit green bar succin alon suffici restor
respir complex inhibit black bar suggest target pro-drug
approach employ effect restor mitochondri function
investig effect patient cell fibroblast isol patient
leigh syndrom diseas occur result recess mutat structur
complex gene respir measur report exhibit
oxygen consumpt rate ocr
baselin reduct respir leigh syndrom fibroblast light blue
bar left panel compar control cell line pink bar left panel howev presenc
ocr patient cell dark blue bar left panel similar untreat control
cell pink bar left panel remark rotenon inhibit complex elicit
similarli robust respiratori activ control dark red bar right panel leigh patient cell
dark blue bar right panel suggest succin pro-drug effect restor
mitochondri function presenc small molecule- disease-induc inhibit
complex result suggest could restor mitochondri function lhon cell
eye
current lead-optim stage preclin develop compani plan
continu preclin develop investig ocular drug deliveri strategi well
vitro vivo efficaci safeti profil fortifi expect select lead candid
develop program
sever candid current develop treatment lhon gensight
sight uncov develop intravitr inject gene
therapi current phase clinic test drug show improv best-
correct visual acuiti bcva sustain etdr letter howev fortifi note
kol believ gensight program look promis sham-treat eye demonstr
page
gain etdr letter statist signific eye
addit stealth biotherapeut mito uncov develop elamipretid
peptid deliv topic eye drop design stabil cardiolipin howev phase ii
reach primari endpoint dont believ stealth viabl competitor fortifi final
sann uncov receiv market author ema
idebenon antioxid inhibitor lipid peroxid facilit
mitochondri electron flux bypass complex administ oral mg/day
week drug sustain benefici effect prevent vision impair
promot vision recoveri measur least worsening/best recoveri visual acuiti patient
howev compani current market us fortifi note us market still
wide open potenti world-wide non-inferior idebenon
page
n-acetylaspart naa one abund molecul mammalian central nervou
system function maintain fluid balanc brain sourc acet
myelin synthesi oligodendrocyt naa synthes neuron broken
aspartoacylas aspa essenti enzym produc oligodendrocyt
develop mainten white matter brain canavan diseas loss-of-funct
mutat occur aspa gene lead naa accumul shown exhibit
nerv damag happen result reduct downstream byproduct
naa hydrolysi includ acet acet essenti myelin neuron deplet
level result nerv demyelin result patient canavan develop cognit
dysfunct neurodegener
canavan autosom recess diseas mean individu heterozyg
mutat aspa asymptomat patient homozyg mutat present lack
muscl tone lack visual fixat earli first week life children
canavan also unusu larg head size macrocephali experi irrit
difficulti feed swallow seizur sleep disturb result neuron
damag caus naa build-up diseas progress fatal mortal often
occur earli childhood typic age patient live adolesc
fewer live adulthood compani estim current preval canavan diseas
approxim patient us eu new case per year us eu
israel diseas preval among ashkenazi popul occur rate ten-
time higher averag
interestingli canavan diseas first disord treat gene
therapi earli thoma jefferson univers treatment deliv
human aspa gene directli patient brain demonstr long-term safeti efficaci
phase ii clinic trial specif treatment reduc naa level
page
slow brain atrophi reduc frequenc seizur canavan patient howev due
fund issu drug never made phase non-gen therapi strategi
actalzolamid epilepsi drug lipoic acid acet supplement aspa enzym
replac therapi fail improv myelin reduc naa level anim
model patient result current approv therapi canavan leav
great need effect therapi treat rare vulner popul therefor
treatment canavan simpli palli consist nutrit hydrat support
protect airway physic therapi special educ gastrostomi help food
intak hydrat
aspa develop self-complementari adeno-associ viral vector
gene therapi restor function aspa gene express brain potenti
cur treatment canavan directli address underli genet caus diseas
deliv function copi aspa gene use brain-penetr deliveri
vector gmp manufactur partnership proof
concept manufactur brain well-establish multipl clinic
program includ axov current phase gangliosidosi
avexi current phase spinal muscular atrophi de-risk
program drug saw signific treatment-rel advers event interest
drug administ intraven iv compani believ import
aspa express cell bodi oligodendrocyt therefor
system deliveri drug singl dose treat patient holist engag
everi cell may capabl express aspa importantli vector capabl
cross blood-brain barrier therefor reach critic brain oligodendrocyt
compani believ one key player like mani restor prevent neuron
damag
compani licens vector umass medic less year ago
develop dr guangp gao renown leader aav gene therapi lead expert
canavan diseas co-found compani dr gao serv advisori board along
dr paola leon experienc leader gene transfer approach treatment
neurolog disord dr leon actual head gene therapi canavan diseas
discuss therefor experi work directli gene therapi canavan
diseas clinic aspa discoveri program head expert signific experi
clinic develop agent treat rare neurodegen disord gene therapi
compani includ biomarin cover raymond cover
raymond novarti nv uncov
paper ahm et al publish aspa gene therapi result rescu earli
lethal improv overal myelin aspa knockout ko mice model
motor function howev abnorm persist neuron myelin respons
lack durabl group improv upon first gener express cassett
increas aspa express incorpor either half gener full gener
kozak sequenc use assur protein express codon-optim
cdna paper publish gessler et al optim express cassett
deliv iv aspa ko mice one day birth per group shown exhibit
treatment restor vivo aspa protein express left panel normal actin western
blot reduc naa level right panel normal total creatin magnet reson
page
gener indistinguish wt significantli improv control
untreat ko mice term aspa gene express
gener respect naa level gener data suggest
group develop highli express vector effect deliv aspa gene
gener therapi
shown exhibit deliveri aspa gene result improv motor
function aspa ko mice per group
one month treatment generation-tr mice perform well wild type wt
acceler rotarod test remark generation-tr mice actual
outperform wt mice test entir durat studi
suggest treatment aspa gene therapi sustain improv motor function aspa-
defici mice data translat human improv could life-chang
canavan patient whose motor skill significantli impair
demonstr effect aspa gene therapi mitig neuropatholog
aspa defici generationtr mous brain indistinguish wt
per group measur mri exhibit
page
brain patholog measur mri decay signal increas signal indic
vacuol brain featur canavan diseas generation-
treat mice show low signal similar wildtyp mice effect
decay signal also sustain durat studi level rescu
seen previou gene therapi canavan compani believ
meaning correct canavan patient brain patholog
date one patient treat vg/kg iv vg via
intracerebroventricular icv administr simultan patient treat
compassion use month post-infus mri scan patient brain
demonstr low signal indic provid sustain reduct brain
vacuol decreas brain edema exhibit
accord compani patient also demonstr improv remyelin neuron
improv function motor outcom month suggest may work
page
canavan patient data de-risk clinic program compani
complet ind-en studi next year
compani plan complet rout administr dose find studi well ind-
enabl toxicolog studi year submiss ind compani
also expect purchas prioriti review voucher prv
page
drive gs hf-
gorlin syndrom gs high frequenc basal cell carcinoma hf-bcc similar diseas
patient may develop hundr basal cell carcinoma bcc often requir
surgic intervent format bcc driven mutat
gene caus upregul hedgehog signal exhibit
healthi cell inhibit hedgehog downregul smoothen receptor
current patient gs undergo frequent surgeri bcc sometim mani
surgeri per year patient hf-bcc exhibit mani bcc gs
underli patholog mechan found estim
patient us eu gs patient us eu hf-bcc
oral hedgehog inhibitor fda-approv vismodegib demonstr efficaci
bcc clinic provid proof-of-concept target pathway
unfortun system inhibit hedgehog signal highli toxic inde gs
patient discontinu vismodegib therapi due advers event includ hair loss muscl
cramp tast loss
pellepharm believ topic formul hedgehog inhibitor could effect treat
bcc yet avoid toxic observ system hedgehog inhibit compani
develop patidegib topic formul small molecul hedgehog inhibitor
inhibit smoothen single-digit nanomolar concentr inhibit smoothen
rescu inhibitori signal hedgehog signal lost patient
across sever clinic studi pellepharm found applic patidegib gel deliv
high concentr drug local tumor avoid system exposur deliv
measur level efficaci result fewer safeti toler concern oral
inhibitor fact notabl hair loss muscl cramp tast loss report patidegib-
treat patient phase ii studi gs power robust statist signific
across cohort patidegib-tr patient complet regress target
reduct number new surgically-elig format base
result patidegib receiv breakthrough therapi design fda
page
base phase ii result leo pharma privat enter research collabor
bridgebio mileston total across investor importantli agreement
includ fund phase trial leo retain option acquir pellepharm upon phase
data payabl bridgebio split option execut
consider commerci mileston bridgebio anticip mileston
award assum
commerci develop leo pharma pay mid single-digit flat royalti payabl bridgebio
sale excess begin bridgebio paid total
royalti royalti transit date bridgebio manag estim royalti transit
date occur
phase trial gs patient current enrol compani plan enrol patient
histolog confirm bcc patient random receiv
patidegib gel vehicl primari endpoint number new surgic elig bcc
nseb month one measur found significantli reduc
phase ii trial post-hoc analysi first patient enrol march
compani expect complet enrol base timelin compani anticip
nda submiss commerci launch
base similar mechan action pellepharm also evalu patidegib phase iib
clinic trial hf-bcc patient compani plan hf-bcc registr trial begin
page
protein tyrosin phosphatas ptp import class enzym play key role
regul cellular signal remov phosphat group target substrat ptp
mediat chang target function subcellular locat homolog region
protein tyrosin phosphatas encod gene well-known
member ptp famili act downstream receptor tyrosin kinas mapk
signal pathway interact receptor tyrosin kinas rtk scaffold protein
immun inhibitori receptor describ dual role tumorigenesi aberr
signal promot tumor growth upregul ra mapk signal
promot t-cell inactiv amplif signal
demonstr posit contributor growth signal
pathway upstream ra mapk activ cancer cell exhibit
upregul mapk signal core featur pathophysiolog numer
cancer includ rtk genet alter rtk gene fusion cancer
driven chronic kras/mapk signal blockad could effect
reduc activ key oncogen driver inde preclin studi shown
inhibit effect treat rtk-driven alk egfr kras-
driven tumor mutant wt amplif lof
clear role promot signal t-cell serv limit
page
t-cell activ suppress t-cell activ dephosphoryl
lck turn limit signal major histocompat complex
mhc therefor inhibit could promot anti-tumor activ t-cell
potenti combin well inhibitor addit preclin studi
shown inhibit found enhanc anti-tumor immun signal
includ t-cell antigen receptor/co-receptor ifn receptor signal pathway
given potenti util inhibit kol view combin kra inhibit
power duo concurr evalu inhibitor monotherapi mirati
jnj/wellspr proactiv develop combin strategi well underway kol note
even shutdown ra still leav residu erk activ addit inhibitori
pressur mapk need optim kra inhibit strategi previou interact
kol believ upregul wildtyp rtk signal like feedback mechan
occur kra blockad believ pan-rtk inhibit approach hammer-
like inhibitor success pair mek inhibitor could
provid benefit kol agre ra pathway easili sidestep mono-select
navir develop potenti best-in-class alloster small molecul
inhibitor current preclin develop design bind catalyt n-
domain simultan stabil close inact conform
compani believ success lockdown mechan may reduc
amount activ protein cell prevent subsequ downstream signal
nomin seri second-gener inhibitor
optim minim off-target activ herg potassium channel import
off-target inhibit herg channel associ cardiac toxic observ
page
inhibitor develop preclin pk studi rodent dog
monkey navir second-gener seri inhibitor demonstr favor
concentr circul support qd dose patient importantli consist
compani vitro herg assay qt/qtc prolong observ dog
date compani shown highly-pot vitro phospho-erk
cell line monotherapi inhibit ra mapk signal induc strong
anti-prolif effect kra mutant pancreat cell line also
demonstr activ rtk-driven esophag squamou cell carcinoma escc xenograft
experi navir found demonstr dose-depend anti-tumor
effect rtk-driven escc model day dose
compani shown exhibit synergi xenograft model variou
standard care target immunotherapi includ mek trametinib miapaca
egfr osimertinib nsclc liver cancer model nsclc model
particular abl restor sensit egfr-mut nsclc xenograft tumor
egfr target therapi result tumor regress exhibit
page
ind-en studi on-going ind submiss plan
first-in-human clinic trial start navir intend develop
monotherapi combin standard care tyrosin kinas inhibitor treat cancer
driven hyperact rtk mapk signal
signific number preval cancer genotyp predict benefit inhibit
includ rtk driver mutat alk egfr ret ras-
driven tumor kra mutant lof wildtyp kra amplif combin
inhibitor varieti context thu navir believ target popul
could amount hundr thousand patient us eu exhibit
page
three inhibitor similar mechan action current phase test
enter novarti nv uncov evalu advanc egfr-mut nsclc
kras-mut nsclc escc head neck scc howev novarti may
observ cardiovascular toxic signal dose intermitt note
novarti recent enter clinic develop partnership mirati cover
van buren evalu combin plu mirati kra inhibitor
revolut medicin privat evalu advanc relaps refractori solid
tumor focu kras-driven tumor similar novarti compound howev
appear toxic concern includ cardiovascular toxic recent revolut
medicin sign deal sanofi sni uncov total cash consider
up-front mileston privat evalu jab-
dose escal studi nsclc head neck esophag cancer china
us addit clinic stage program redx pharma
preclin develop respect asset
given competit space compani current evalu clinic strategi
note potenti proof-of-concept monotherapi could achiev patient
fail precis oncolog tki patient similar novarti current enrol
eventu navir believ could use combin agent tki
page
ferroptosi form iron-depend oxid non-apoptot program cell death
result toxic accumul lipid free radic howev similar mechan
program cell death apoptosi cancer cell learn avoid ferroptosi recent literatur
suggest glutathion peroxidas essenti enzym protect cancer cell
ferroptosi lipid free radic neutral activ reason believ
inhibit could effect strategi treat cancer exhibit
inhibit aim induc ferroptosi cancer cell compani
believ util inhibit analog success inhibitor
class venetoclax reason believ inhibit could use
clinic single-ag combin therapi deplet persist standard care
treatment-toler cancer cell treat tumor type demonstr de novo sensit
inhibit target therapy-induc dedifferentiation/resist
lead program develop highli potent select oral
irrevers compound target discoveri program head advis
expert ferroptosi chemistri includ frank mccormick ucsf matt hangauer ucsd
anjali pandey kevan shokat ucsf scott dixon stanford note one
compani work develop inhibitor activ
program led bayer bayri uncov broad institut
preclin data gener other suggest mani common cancer
sensit inhibit exhibit
page
compil dataset cell-bas screen cancer cell-lin deriv
tumor type cell line consid sensit inhibit show
nm less denot light blue dark blue color base
vitro studi believ inhibit could address renal cell carcinoma rcc
nsclc breast cancer melanoma
initi proof-of-concept experi demonstr inhibit impair
tumor growth xenograft model sarcoma show decreas tumor growth
rel vehicl treat anim exhibit
experi compound found well-toler full dose period
indic anim stabl bodi weight observ clear target engag
sever normal tissu includ kidney liver lung heart pancrea suggest
ferroptosi uniqu sensit mechan cancer cell leav healthi cell intact
page
result support literatur demonstr tumor regress use genet inactiv
model rcc melanoma sarcoma
base vitro vivo work conduct date believ certain cancer type
could sensit inhibit single-ag cancer may requir
combin therapi singl agent compani believ inhibit could
effect rcc pancreat cancer nhl sarcoma given sensit profil demonstr
exhibit potenti combin agent studi shown treat cell line
nsclc braf melanoma breast standard care agent
chemotherapi target therapi respect kill cell remain
could sensit inhibit togeth cancer account
new case year us indic success inhibitor could result
team continu work understand underli biolog fulli
lead seri compound demonstr abil induc ferroptosi give
compani confid drug candid select next year current work
continu lead optim expand vivo proof concept ahead clinic candid
select subsequ initi ind-en studi
page
risk associ bridgebio common biotech compani describ
detail
clinic risk success clinic trial essenti bridgebio subsidiari
partner market product success clinic guarante invest thesi
overweight rate larg assum success develop infigratinib bbp-
regulatori risk fda ema regulatori bodi may differ view
benefit-risk balanc demonstr clinic test compani seek approv bridgebio
subsidiari may requir addit trial may make develop
candid time cost-prohibit assum success regulatori review
commerci risk cardiovascular oncolog rare diseas gene therapi space
infigratinib respect oper specif
challeng multipl competitor signific price pressur addit
infigratinib success develop enter
market sever therapi market and/or close develop clinic
and/or regulatori success guarante commerci success
financ risk bridgebio pipelin develop commerci plan requir capit
time addit cash flow market product fund partner bridgebio may
need rais money equiti offer may neg impact stock price
intellectu properti risk protect bridgebio drug process depend issu
pend patent in-hous knowledg one parti often challeng intellectu
properti estat success product claim prioriti patent patent
invalid infring signific expens legal protect could requir futur
guarante success
page
phase ii basket trial enrol osu/orien consortium
rcc pancreat nhl sarcoma
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
